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1. INTRODUCTION 
 Plants are essential components of the universe. After various observations 
and experimentations many medicinal plants were identified as source of important 
medicine. Medicinal plants have been used since prehistoric period for the cure of 
various diseases.1  
About 8,000 herbal remedies have been described in Ayurveda. The  
Rig-Veda (5000 BC) has recorded 67 medicinal plants, Yajurveda 81 species, 
Atharvaveda (4500-2500 BC) 290 species, Charak Samhita (700 BC) and Sushrut 
Samhita (200 BC) had described properties and uses of 1100 and 1270 species 
respectively. In compounding of drugs and these are still used in the classical 
formulations and in the Ayurvedic system of medicine. From time immemorial man 
depended on plants derived medicines, it is evident that the fascination for plants is 
as old as mankind itself. The plant kingdom represents a rich storehouse of organic 
compounds, many of which have been used for medical purpose and could serve as 
lead for the development of novel agents having good efficacy in various 
pathological disorders.2 
 The World Health Organization (WHO) estimates that about 80% of 
population living in the developing countries relies on traditional medicines for their 
primary health care needs. In almost all the traditional system of medicines, the 
medicinal plants play a major role and constitute the backbone. A large body of 
evidence has collected to show potential of medicinal plants used in various 
traditional systems. In the last few years more than 13 000 plants have been studied 
for the various diseases and ailments all over the world.3 
Herbal medicine is the study and use of medicinal properties of plants. Plants 
have the ability to synthesize a wide variety of chemical compounds that are used to 
perform important biological functions. Most of the phytochemical beneficial effects 
consumed by human beings, they are used effectively treat to human disease. At 
least 12,000 such compounds have been isolated so far; a number estimated to be 
less than 10% of the total. Chemical compounds in plants mediated their effects on 
the human body through processes identical to those already well understood for the 
chemical compounds in conventional drugs; thus herbal medicines do not differ 
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greatly from conventional drugs in terms of how they work. This enables herbal 
medicines to be as effective as curative medicines.4  
In general, traditional practitioners used crude drug either in fresh juice or 
decoction for healing various ailments. The medicinal plants belonging to established 
system of medicine i.e. Ayurveda, Unani and Siddha were used by the traditional folk 
healers. They used crude drugs in single or combination of drugs for the treatment of 
different diseases.  
Considerable research on Pharmacognosy, Chemistry, Pharmacology and 
Clinical therapeutics has been carried out on native medicinal plants. Traditional 
knowledge driven drug development can follow a reverse pharmacology path and 
reduce time and cost of development. 
In Indian system of medicine several herbal remedies has been tried for the 
treatment of kidney failure since the time of charka and sushruta. New approaches to 
improve and accelerate the joint drug discovery and development process are 
expected to take place mainly from innovation in drug target elucidation and lead 
structure discovery.5 
Extracts and metabolites of the plant particularly those from leaves and fruits 
possess useful pharmacological activities. The fruits are utilized as vegetable and 
regarded as essential ingredient in the South Indian diet.6, 7 
Ethnobotanical studies are often significant in revealing locally important plant 
species especially for the discovery of crude drug.8 
Allopathy is a system of medicines with full of side effects, in lay man’s words 
but any how this has become a synonym for evidence based system of medicine or 
modern medicine. Allopathy is totally a system of physical health and moreover this 
science has become a bio-engineering and bio-mechanical system of medicines, 
where they believe to replace or change of the organs or systems in name of 
treatment, not much worried about the cure. The allopathic medicines keep on 
suppressing the signs and symptoms alone, not concerned with the Root Cause of a 
disease. As modern sciences believe in suppressing the signs and symptoms, these 
never appreciate to remove the disease causing factors from the body.  Due to these 
disadvantages of allopathic medicines nowadays the herbal drugs are mostly 
preferred than the allopathic medicines.9 
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Traditional knowledge will serve as a powerful search engine and most 
importantly, will greatly facilitate intentional, focused and safe natural product 
research to rediscover the drug discovery process. Therefore, search of 
Nephroprotective herbs from medicinal plants has become important and need of the 
day.10 
Considering this situation, I selected Tamarindus indica linn for the evaluation 
of its Nephroprotective activity. 
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2. REVIEW OF LITERATURE 
2.1 KIDNEY-INTRODUCTION 
The kidney is an excretory organ. It is located on the posterior abdominal wall, 
one on each side of the lumbar part of the vertebral column. They reside against the 
back muscles in the upper abdominal cavity. They sit opposite each other on either 
side of the spine. The right kidney sits a little bit lower than the left to accommodate 
the liver.11 
 The formation of urine is achieved through the processes of filtration,                    
re-absorption, and secretion by the glomeruli and tubules within the kidney. The 
bladder stores urine that it received from the kidney by the way of ureters. Urine is 
then excreted from the body through urethra. 
 The main function of the kidney is excretion of waste products like urea, uric 
acid, creatinine, etc. 
 It also regulates the blood contents of Nacl and other electrolytes, as well as 
the volume of extracellular fluid to maintain homeostasis and regulate blood 
pressure. 
 It plays a crucial role in maintaining acid-base balance. 
 It is responsible for re-absorption of water, glucose and amino acids. 
 It helps with synthesis of local hormones like angiotensin, prostacyclin and 
erythropoietin. 
 It is also involved in the hydroxylation of vitamin D. 
 It also eliminates the poisons from the blood. 
 It is the major excretory part for drug metabolites. 
NEPHRON 
The Nephron is the basic structural and functional unit of the kidney.12 Its 
functions are vital to life and are regulated by the endocrine 
system by hormones such as antidiuretic hormone, aldosterone, thyroid 
and parathyroid hormone.13 In humans, a normal kidney contains 800,000 to 1.5 
million of Nephrons.14 
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2.1.1 ANATOMY OF NEPHRON 
 
 
Fig.1: Anatomy of Nephron 
The labelled parts are,  
1. Glomerulus, 2. Efferent arteriole, 3. Bowman's capsule, 4. Proximal convoluted 
tubule, 5. Cortical collecting duct, 6. Distal convoluted tubule, 7. Loop of Henle,  
8. Papillary duct, 9. Peritubular capillaries, 10. Arcuatevein, 11. Arcuateartery,  
12. Afferent arteriole, 13. Juxtaglomerular apparatus. 
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2.1.2 HISTOLOGY
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 Nephron histology studies the structure of the Nephron as viewed under 
a microscope. Various distinct cell types occur in the Nephron, which include: 
Each Nephron is composed of an initial filtering component  
(the "renal corpuscle") and a tubule specialized for re-absorption and secretion  
(the "renal tubule"). The renal corpuscle filters out solutes from the blood, delivering 
water and small solutes to the renal tubule for modification. 
Renal corpuscle 
It is composed of a glomerulus and Bowman's capsule, the renal 
corpuscle (or Malpighian corpuscle) is the beginning of the Nephron. It is the 
Nephron's initial filtering component. 
Glomerulus 
The glomerulus is a capillary tuft that receives its blood supply from an 
afferent arteriole of the renal circulation. The glomerular blood pressure provides the 
driving force for water and solutes to be filtered out of the blood and into the space 
made by Bowman's capsule. 
The remaining blood (only approximately 1/5 of all plasma passing through 
the kidney is filtered through the glomerular wall into the Bowman's capsule) passes 
into the efferent arteriole. The diameter of efferent arterioles is smaller than that of 
afferent arterioles, increasing the hydrostatic pressure in the glomerulus. 
Bowman's capsule 
The Bowman's capsule, also called the glomerular capsule, surrounds the 
glomerulus. It is composed of a visceral inner layer formed by specialized cells 
called podocytes, and a parietal outer layer composed of simple squamous 
epithelium. Fluids from blood in the glomerulus are filtered through the visceral layer 
of podocytes, resulting in the glomerular filtrate. 
The glomerular filtrate then moves to the renal tubule, where it is further 
processed to form urine. The different stages of this fluid are collectively known as 
the tubular fluid. 
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Renal tubule 
The renal tubule is the portion of the Nephron containing the tubular 
fluid filtered through the glomerulus.16 After passing through the renal tubule, the 
filtrate continues to the collecting duct system.17 
The components of the renal tubule are: 
• Proximal convoluted tubule (lies in cortex and lined by simple cuboidal 
epithelium with brush borders which help to increase the area of absorption 
greatly.) 
• Loop of Henle (hair-pin like i.e. U-shaped and lies in medulla)                                                                                                  
• Descending limb of loop of Henle 
The descending limb of loop of Henle is divided into 2 segments: 
• Thick descending limb of loop of Henle (Begins from PCT-proximal 
convoluted tubule.) 
• Thin descending limb of loop of Henle 
• Ascending limb of loop of Henle 
The ascending limb of loop of Henle is divided into 2 segments: Lower end 
of ascending limb is very thin and is lined by simple squamous epithelium. 
The distal portion of ascending limb is thick and is lined by simple cuboidal 
epithelium. 
o Thin ascending limb of loop of Henle 
o Thick ascending limb of loop of Henle (enters cortex and becomes 
DCT-distal convoluted tubule.) 
• Distal convoluted tubule 
Blood from the efferent arteriole containing everything that was not filtered out 
in the glomerulus, moves into the peritubular capillaries tiny blood vessels that 
surround the loop of Henle and the proximal and distal tubules, where the tubular 
fluid flows. Substances then reabsorb from the latter back to the blood stream.  
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The peritubular capillaries then recombine to form an efferent venule, which 
combines with efferent venules from other Nephrons into the renal vein, and rejoins 
the main bloodstream. 
2.1.3 Classes of Nephron 
There are two general classes of Nephrons. They are, 
a) Cortical Nephrons 
b) Juxtamedullary Nephrons 
Both of which are classified according to the length of their associated Loop of 
Henle and location of their renal corpuscle. All Nephrons have their renal corpuscles 
in the cortex. Cortical Nephrons have their Loop of Henle in the renal medulla near 
its junction with the renal cortex, while the Loop of Henle of juxtamedullary Nephrons 
is located deep in the renal medulla; they are called juxtamedullary because their 
renal corpuscle is located near the medulla (but still in the cortex). The nomenclature 
for cortical Nephrons varies, with some sources distinguishing between superficial 
cortical Nephrons and midcortical Nephrons, depending on where their corpuscle is 
located within the cortex.18 
The majority of Nephrons are cortical. Cortical Nephrons have a shorter loop 
of Henle compared to juxtamedullary Nephrons. The longer loop of Henle in 
juxtamedullary Nephrons create a hyperosmolar gradient that allows for the creation 
of concentrated urine.19 
The peritubular capillaries surround the proximal and distal tubules in both 
classes of Nephrons. However, they surround the loop of Henle, forming the  
vasa recta, only in juxtamedullary Nephrons and not in cortical Nephrons. 
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2.1.4 Functions of Nephron
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The Nephrons carried out nearly all of the kidney’s function. Most of these 
functions are reabsorption and secretion of various solutes such as ions, 
carbohydrates and amino acids. 
 
Fig.2: Functions of Nephron 
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The major functions of Nephrons are, 
 Regulation of the concentration of water and soluble substances like sodium 
salts by filtering the blood 
 Re-absorption of what is needed and excreting the rest as urine. 
 Elimination of wastes from the body 
 Regulates blood volume 
 Regulates blood pressure 
 Controls levels of electrolytes and metabolites 
 Regulates blood pH. 
Each segment of the Nephron has highly specialized functions. 
2.1.4.1 Functions of Proximal convoluted tubule 
Fluid in the filtrate entering the proximal convoluted tubule is reabsorbed into 
the peritubular capillaries, including approximately two-thirds of the filtered salt and 
water and all filtered organic solutes (primarily glucose and amino acids). 
2.1.4.2 Functions of loop of Henle 
The loop of Henle is a U-shaped tube that extends from the proximal tubule. It 
consists of a descending limb and an ascending limb. It begins in the cortex, 
receiving filtrate from the proximal convoluted tubule, extends into the medulla as the 
descending limb, and then returns to the cortex as the ascending limb to empty into 
the distal convoluted tubule. 
The primary role of the loop of Henle is to concentrate the salt in the 
interstitium, the tissue surrounding the loop. 
Considerable differences aid in distinguishing the descending and ascending 
limbs of the loop of Henle. The descending limb is permeable to water and 
noticeably less impermeable to salt, and thus only indirectly contributes to the 
concentration of the interstitium. As the filtrate descends deeper into 
the hypertonic interstitium of the renal medulla, water flows freely out of the 
descending limb by osmosis until the tonicity of the filtrate and interstitium 
equilibrate. 
The hypertonicity of the medulla (and therefore concentration of urine) is 
determined in part by the size of the loop of Henle. 
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Unlike the descending limb, the thin ascending limb is impermeable to water, 
a critical feature of the counter current exchange mechanism employed by the loop. 
The ascending limb actively pumps sodium out of the filtrate, generating the 
hypertonic interstitium that drives counter current exchange. In passing through the 
ascending limb, the filtrate grows hypotonic since it has lost much of its sodium 
content. This hypotonic filtrate is passed to the distal convoluted tubule in the renal 
cortex. 
2.1.4.3 Functions of distal convoluted tubule 
The distal convoluted tubule has a different structure and function to that of 
proximal convoluted tubule. Cells lining the tubule have numerous mitochondria to 
produce enough energy (ATP) for active transport to take place. Much of the ion 
transport taking place in the distal convoluted tubule is regulated by the endocrine 
system. In the presence of parathyroid hormone, the distal convoluted tubule 
reabsorbs more calcium and secretes more phosphate. When aldosterone is 
present, more sodium is reabsorbed and more potassium secreted. Atrial natriuretic 
peptide causes the distal convoluted tubule to secrete more sodium. In addition, the 
tubule also secretes hydronium and ammonium cations to regulate urine pH. 
2.1.4.4 Functions of Collecting duct system  
Each distal convoluted tubule delivers its filtrate to a system of collecting 
ducts, the first segment of which is the connecting tubule. The collecting duct system 
begins in the renal cortex and extends deep into the medulla. As the urine travels 
down the collecting duct system, it passes by the medullary interstitium which has a 
high sodium concentration as a result of the loop of Henle's counter current multiplier 
system. 
Though the collecting duct is normally impermeable to water, it becomes 
permeable in the presence of antidiuretic hormone (ADH). ADH affects the function 
of aquaporins, resulting in the re-absorption of water molecules as it passes through 
the collecting duct. Aquaporins are membrane proteins that selectively conduct water 
molecules while preventing the passage of ions and other solutes. As much as 3/4 of 
the water from urine can be reabsorbed as it leaves the collecting duct by osmosis. 
Thus the levels of ADH determine whether urine will be concentrated or diluted. An 
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increase in ADH is an indication of dehydration, while water sufficiency results in a 
decrease in ADH allowing for diluted urine.  
Lower portions of the collecting organ are also permeable to urea, allowing 
some of it to enter the medulla of the kidney, thus maintaining its high concentration 
(which is very important for the Nephron). 
Urine leaves the medullary collecting ducts through the renal papillae, 
emptying into the renal calyces, the renal pelvis, and finally into the urinary 
bladder via the ureter. The collecting duct originates from the ureteric bud.  
2.1.4.5 Functions of juxtaglomerular apparatus 
The juxtaglomerular apparatus is a specialized region of the Nephron 
responsible for production and secretion of the enzyme renin, involved in the renin-
angiotensin system. This occurs near the site of contact between the thick ascending 
limb and the afferent arteriole. It contains three components: Macula densa, 
Juxtaglomerular cells and Extraglomerular mesangial cells. 
2.1.5 Pathology of Nephron (kidney)
20,21,22
 
 Nephrotic Syndrome 
The Nephrotic syndrome is a condition marked by very high levels of protein 
in the urine; low levels of protein in the blood; swelling, especially around the eyes, 
feet, and hands; and high cholesterol. 
The Nephrotic syndrome is a set of symptoms, not a disease in itself. It can 
occur with many diseases, so prevention relies on controlling the diseases that 
cause it. Treatment of the Nephrotic syndrome focuses on identifying and treating 
the underlying cause, if possible, and reducing high cholesterol, blood pressure, and 
protein in the urine through diet, medication, or both. 
The Nephrotic syndrome may go away once the underlying cause, if known, is 
treated. However, often a kidney disease is the underlying cause and cannot be 
cured. In these cases, the kidneys may gradually lose their ability to filter wastes and 
excess water from the blood. If kidney failure occurs, the patient will need to be on 
dialysis or have a kidney transplant. 
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 Pyelonephritis (Infection of kidney pelvis) 
Bacteria may infect the kidney, usually causing back pain and fever. A spread 
of bacteria from an untreated bladder infection is the most common cause of 
pyelonephritis. 
 Polycystic kidney disease 
A genetic condition resulting in large cyst in the kidney that impair their 
functions. 
 Hypertensive nephropathy 
It is the damage of kidney caused by high blood pressure. Chronic renal 
failure may eventually result. 
 Kidney cancer 
Renal cell carcinoma is the most common cancer affecting the kidney. 
Smoking is the most common cause of kidney cancer. 
 Interstitial nephritis 
Inflammations on the connective tissues of the kidney, which often causing 
acute renal failure, allergic reactions and drug side effects are the usual causes. 
 Kidney stones (Urolithiasis) 
Minerals in the urine form crystals (stones), which may grow large enough to 
block urine flow. It is considered as one of the most painful conditions. Most kidney 
stones pass on their own but some are too large and need to be treated. 
 Glomerulonephritis 
It describes the inflammation of the membrane tissue in the kidney that serves 
as a filter, separating wastes and extra fluid from the blood. 
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 Glomerulosclerosis 
It describes the scarring or hardening of the tiny blood vessels within the 
kidney. 
 Lupus nephritis 
It is the name given to the kidney disease caused by Systemic lupus 
erythematosus (SLE), and it occurs when auto-antibodies form or are deposited in 
the glomeruli, causing inflammation. Ultimately, the inflammation may create scars 
that keep the kidneys from functioning properly. Conventional treatment for lupus 
nephritis includes a combination of two drugs, cyclophosphamide, a cyotoxic agent 
that suppresses immune system, prednisolone, it is a corticosteroid used to reduce 
inflammation. A newer immunosuppressant, mychophenolate mofetil (MMF), has 
been used instead of cyclophosphamide. Preliminary studies indicate that MMF may 
be as effective as cyclophosphamide and has milder side effects. 
 Goodpasture's Syndrome 
It involves an autoantibody that specifically targets the kidneys and the lungs. 
Often, the first indication that patients have the autoantibody is when they cough up 
blood. But lung damage in Goodpasture's Syndrome is usually superficial compared 
with progressive and permanent damage to the kidneys. Goodpasture's Syndrome is 
a rare condition that affects mostly young men but also occurs in women, children, 
and older adults. Treatments include immunosuppressive drugs and a blood-
cleaning therapy called plasmapheresis that removes the auto antibodies. 
 IgA nephropathy 
It is a form of glomerular disease that results when immunoglobulin A (IgA) 
forms deposits in the glomeruli, where it creates inflammation. IgA nephropathy was 
not recognized as a cause of glomerular disease until the late 1960s, when 
sophisticated biopsy techniques were developed that could identify IgA deposits in 
kidney tissue. 
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The most common symptom of IgA nephropathy is blood in the urine, but it is 
often a silent disease that may go undetected for many years. The silent nature of 
the disease makes it difficult to determine how many people are in the early stages 
of IgA nephropathy, when specific medical tests are the only way to detect it. It 
appears to affect men more than women. Although IgA nephropathy is found in all 
age groups, young people rarely display signs of kidney failure because the disease 
usually takes several years to progress to the stage where it causes detectable 
complications. 
No treatment is recommended for early or mild cases of IgA nephropathy 
when the patient has normal blood pressure and less than 1 gram of protein in a  
24-hour urine output. 
When proteinuria exceeds 1 gram/day, treatment is aimed at protecting 
kidney function by reducing proteinuria and controlling blood pressure. Blood 
pressure medicines angiotensin converting enzyme inhibitors (ACE inhibitors) or 
angiotensin receptor blockers (ARBs) that block a hormone called angiotensin are 
most effective at achieving those two goals simultaneously. 
 Hereditary Nephritis-Alport Syndrome 
The primary indicator of Alport syndrome is a family history of chronic 
glomerular disease, although it may also involve hearing or vision impairment. This 
syndrome affects both men and women, but men are more likely to experience 
chronic kidney disease and sensory loss. Men with Alport syndrome usually first 
show evidence of renal insufficiency while in their twenties and reach total kidney 
failure by age 40. Women rarely have significant renal impairment, and hearing loss 
may be so slight that it can be detected only through testing with special equipment. 
Usually men can pass the disease only to their daughters. Women can transmit the 
disease to either their sons or their daughters. Treatment focuses on controlling 
blood pressure to maintain kidney function. 
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 Infection-related Glomerular Disease 
Glomerular disease sometimes develops rapidly after an infection in other 
parts of the body. 
 Acute post-streptococcal glomerulonephritis (PSGN) 
It can occur after an episode of strep throat or, in rare cases, impetigo (a skin 
infection). The Streptococcus bacteria do not attack the kidney directly, but an 
infection may stimulate the immune system to overproduce antibodies, which are 
circulated in the blood and finally deposited in the glomeruli, causing damage. PSGN 
can bring on sudden symptoms of swelling (edema), reduced urine output (oliguria), 
and blood in the urine (hematuria). Tests will show large amounts of protein in the 
urine and elevated levels of creatinine and urea nitrogen in the blood, thus indicating 
reduced kidney function. High blood pressure frequently accompanies reduced 
kidney function in this disease. 
PSGN is most common in children between the ages of 3 and 7, although it 
can strike at any age, and it most often affects boys. It lasts only a brief time and 
usually allows the kidneys to recover. In a few cases, however, kidney damage may 
be permanent, requiring dialysis or transplantation to replace renal function. 
 HIV infection 
The virus that leads to acute immune deficiency syndrome (AIDS), can also 
cause glomerular disease. Between 5 and 10 percent of people with HIV experience 
kidney failure, even before developing full-blown AIDS. HIV-associated nephropathy 
usually begins with heavy proteinuria and progresses rapidly (within a year of 
detection) to total kidney failure. Researchers are looking for therapies that can slow 
down or reverse this rapid deterioration of renal function, but some possible solutions 
involving immune suppression are risky because of the patients' already 
compromised immune system. 
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 Glomerulo sclerosis 
It is scarring (sclerosis) of the glomeruli. In several sclerotic conditions, a 
systemic disease like lupus or diabetes is responsible. Glomerulo sclerosis is caused 
by the activation of glomerular cells to produce scar material. This may be stimulated 
by molecules called growth factors, which may be made by glomerular cells 
themselves or may be brought to the glomerulus by the circulating blood that enters 
the glomerular filter. 
 Diabetic nephropathy 
High blood sugar from diabetes progressively damages the kidneys, 
eventually causing chronic kidney disease. Protein in the urine (Nephrotic syndrome) 
may also result. It is the leading cause of glomerular disease and of total kidney 
failure in the United States. Kidney disease is one of several problems caused by 
elevated levels of blood glucose, the central feature of diabetes. In addition to 
scarring the kidney, elevated glucose levels appear to increase the speed of blood 
flow into the kidney, putting a strain on the filtering glomeruli and raising blood 
pressure. 
Diabetic nephropathy usually takes many years to develop. People with 
diabetes can slow down damage to their kidneys by controlling their blood glucose 
through healthy eating with moderate protein intake, physical activity, and 
medications. People with diabetes should also be careful to keep their blood 
pressure at a level below 140/90 mm Hg, if possible. Blood pressure medications 
called ACE inhibitors and ARBs are particularly effective at minimizing kidney 
damage and are now frequently prescribed to control blood pressure in patients with 
diabetes and in patients with many forms of kidney disease. 
 Focal segmental glomerulosclerosis (FSGS) 
It describes scarring in scattered regions of the kidney, typically limited to one 
part of the glomerulus and to a minority of glomeruli in the affected region. FSGS 
may result from a systemic disorder or it may develop as an idiopathic kidney 
disease, without a known cause. Proteinuria is the most common symptom of FSGS, 
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but, since proteinuria is associated with several other kidney conditions, the doctor 
cannot diagnose FSGS on the basis of proteinuria alone. Biopsy may confirm the 
presence of glomerular scarring if the tissue is taken from the affected section of the 
kidney. But finding the affected section is a matter of chance, especially early in the 
disease process, when lesions may be scattered. 
Confirming a diagnosis of FSGS may require repeat kidney biopsies. Arriving 
at a diagnosis of idiopathic FSGS requires the identification of focal scarring and the 
elimination of possible systemic causes such as diabetes or an immune response to 
infection. Since idiopathic FSGS is, by definition, of unknown cause, it is difficult to 
treat. No universal remedy has been found, and most patients with FSGS progress 
to total kidney failure over 5 to 20 years. Some patients with an aggressive form of 
FSGS reach total kidney failure in 2 to 3 years. Treatments involving steroids or 
other immunosuppressive drugs appear to help some patients by decreasing 
proteinuria and improving kidney function. But these treatments are beneficial to only 
a minority of those in whom they are tried, and some patients experience even 
poorer kidney function as a result. ACE inhibitors and ARBs may also be used in 
FSGS to decrease proteinuria. Treatment should focus on controlling blood pressure 
and blood cholesterol levels, factors that may contribute to kidney scarring. 
 Membranous nephropathy 
Also called membranous glomerulopathy, is the second most common cause 
of the Nephrotic syndrome (proteinuria, edema, high cholesterol) in U.S. adults after 
diabetic nephropathy. Diagnosis of membranous nephropathy requires a kidney 
biopsy, which reveals unusual deposits of immunoglobulin G and complement C3, 
substances created by the body's immune system. Fully 75 percent of cases are 
idiopathic, which means that the cause of the disease is unknown. The remaining 25 
percent of cases are the result of other diseases like systemic lupus erythematosus, 
hepatitis B or C infection, or some forms of cancer. Drug therapies involving 
penicillamine, gold, or captopril have also been associated with membranous 
nephropathy. About 20 to 40 percent of patients with membranous nephropathy 
progress, usually over decades, to total kidney failure, but most patients experience 
either complete remission or continued symptoms without progressive kidney failure. 
Doctors disagree about how aggressively to treat this condition, since about 20 
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percent of patients recover without treatment. ACE inhibitors and ARBs are generally 
used to reduce proteinuria. Additional medication to control high blood pressure and 
edema is frequently required. Some patients benefit from steroids, but this treatment 
does not work for everyone. Additional immunosuppressive medications are helpful 
for some patients with progressive disease. 
 Minimal change disease (MCD) 
It is the diagnosis given when a patient has the Nephrotic syndrome and the 
kidney biopsy reveals little or no change to the structure of glomeruli or surrounding 
tissues when examined by a light microscope. Tiny drops of a fatty substance called 
a lipid may be present, but no scarring has taken place within the kidney. MCD may 
occur at any age, but it is most common in childhood. A small percentage of patients 
with idiopathic Nephrotic syndrome do not respond to steroid therapy. For these 
patients, the doctor may recommend a low-sodium diet and prescribe a diuretic to 
control edema. The doctor may recommend the use of non steroidal anti-
inflammatory drugs to reduce proteinuria. ACE inhibitors and ARBs have also been 
used to reduce proteinuria in patients with steroid-resistant MCD. These patients 
may respond to larger doses of steroids, more prolonged use of steroids, or steroids 
in combination with immunosuppressant drugs, such as chlorambucil, 
cyclophosphamide, or cyclosporine. 
 Renal failure 
Renal failure is any acute or chronic loss of kidney function and is the term 
used when some kidney function remains. 
 Acute Renal Failure 
It is the sudden worsening of the kidney functions. Dehydration, a blockage in 
the urinary tract, or kidney damage can cause acute renal failure, which is usually 
reversible. A few forms of glomerular disease cause very rapid deterioration of 
kidney function. For example, PSGN can cause severe symptoms (hematuria, 
proteinuria, edema) within 2 to 3 weeks after a sore throat or skin infection develops. 
The patient may temporarily require dialysis to replace renal function. This rapid loss 
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of kidney function is called acute renal failure (ARF). Although ARF can be life-
threatening while it lasts, kidney function usually returns after the cause of the kidney 
failure has been treated. In many patients, ARF is not associated with any 
permanent damage. However, some patients may recover from ARF and 
subsequently develop CKD. 
 Chronic Kidney Disease 
A permanent partial loss of the functions of the kidney, Diabetes and high 
blood pressure are the most common causes. It is the most forms of glomerular 
disease develop gradually, often causing no symptoms for many years. CKD is the 
slow, gradual loss of kidney function. Some forms of CKD can be controlled or 
slowed down. For example, diabetic nephropathy can be delayed by tightly 
controlling blood glucose levels and using ACE inhibitors and ARBs to reduce 
proteinuria and control blood pressure. But CKD cannot be cured. Partial loss of 
renal function means that some portion of the patient's Nephrons has been scarred, 
and scarred Nephrons cannot be repaired. In many cases, CKD leads to total kidney 
failure. 
 End-stage renal disease (ESRD) 
It is the complete loss of kidney function, usually due to progressive chronic 
kidney disease. People with ESRD require regular dialysis for survival. The Total 
kidney failure, sometimes called end-stage renal disease (ESRD), indicates 
permanent loss of kidney function. Depending on the form of glomerular disease, 
renal function may be lost in a matter of days or weeks or may deteriorate slowly and 
gradually over the course of decades. 
 Total Kidney Failure 
To stay alive, a patient with total kidney failure must go on dialysis hemo-
dialysis or peritoneal dialysis or receive a new kidney through transplantation. 
Patients with CKD who are approaching total kidney failure should learn as much 
about their treatment options as possible so they can make an informed decision 
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when the time comes. With the help of dialysis or transplantation, many people 
continue to lead full, productive lives after reaching total kidney failure. 
2.1.6 SIGNS AND SYMPTOMS OF NEPHRON PATHOLOGY
21
 
• Edema: Swelling caused by the accumulation of fluid in cells and tissues. In 
kidney failure, fluid may collect in the feet, hands, abdomen, or face. 
• Hematuria: Blood in the urine. Blood may turn the urine pink or cola-colored. 
• Hypoproteinemia: Reduced levels of protein in the blood. 
• Proteinuria: Large amounts of protein in the urine, it may cause foamy urine. 
• Uremia: Accumulation of urea and other wastes in the blood. These wastes, 
which become toxic in large amounts, are normally eliminated through 
urination. 
• Albuminuria: Large amounts of protein in the urine 
• Reduced glomerular filtration rate: Inefficient filtering of wastes from the 
blood 
• General ill feeling and fatigue 
• Generalized itching (pruritus) and dry skin 
• Headaches 
• Weight loss without trying to lose weight 
• Appetite loss 
• Nausea 
Other symptoms like, 
• Abnormally dark or light skin 
• Bone pain 
• Brain and nervous system symptoms 
• Drowsiness and confusion 
• Problems concentrating or thinking 
• Numbness in the hands, feet, or other areas 
• Muscle twitching or cramps 
• Breath odour 
• Easy bruising, bleeding, or blood in the stool 
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• Excessive thirst 
• Frequent hiccups 
• Low level of sexual interest and impotence 
• Menstrual periods stop (amenorrhea) 
• Sleep problems, such as insomnia, restless leg syndrome, and obstructive 
sleep apnea 
• Swelling of the feet and hands (edema) 
• Vomiting, typically in the morning 
2.1.7 DISEASES AND CONDITIONS
21
 
o Autoimmune disease 
It is a disease in which the body's own disease-fighting cells attack the body 
itself. 
o Hypertension 
It is a condition that can cause kidney damage or be caused by kidney 
disease. 
o Idiopathic disease 
It is a type of disease that occurs without a known cause. 
o Nephrotoxic 
It is the damaging to the kidneys. 
o Sclerotic disease 
It is a disease in which tissues become hardened or scarred. 
o Systemic disease 
It is a disease that affects multiple parts of the body, often as a result of 
substances circulating in the blood. 
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2.2 NEPHROTOXICITY 
Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some 
substances, both toxic chemicals and medications, on renal function. There are 
varies forms, and some drugs may affect renal function in more than one way. 
Nephrotoxins are substances which displaying Nephrotoxicity. Nephrotoxicity should 
not be confused with the fact that some medications have a predominantly renal 
excreation and need their dose adjusted for the decreased renal function (example: 
heparin).23 
Kidney failure is the one of the most common diseases in India. The world 
health organisation recognizes four major groups of renal failure according to the 
predominant involvement of corresponding morphologic component. 
i. Glomouruler diseases, 
ii. Tubular diseases, 
iii. Interstitial diseases and 
iv. Vascular diseases.  
And also two major stages viz. 
a) Acute renal failure – it is a syndrome charecterised by rapid onset of renal 
dysfunction, chiefly oliguria or anuria, and sudden increase in metabolic waste 
product in the blood and secondly 
b) Chronic renal failure – it is a syndrome charecterised by progressive and 
irreversible deterioration of renal function due to slow destruction of renal 
parenchyma eventually terminating in death. 
Many plants have been used for the treatment of kidney failure in traditional 
system of medicine throughout the world. Indeed along with the dietary measures, 
plant preparation formed the basis of the treatment of the disease until the 
introduction of allopathic medicine. Ethnomedicinal plants can be used to help 
forestall the need of dialysis by treating the causes and effect of renal failure, as well 
as reducing the many adverse effect of dialysis.24 
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There are few chemical agents to treat acute renal failure. Studies reveal back 
synthetic Nephroprotective agents have adverse effect besides reduce 
Nephrotoxicity, various environmental toxical and clinically useful drugs, 
acetaminophen, gentamycin and Cisplatin, can cause severe organ toxicities through 
the metabolic activation to highly reactive free radicals.25 
The term acute renal failure (ARF) is currently substituted by acute kidney 
injury (AKI). Acute kidney injury is a reversible condition in which there is a sudden 
decline in renal function, manifested by hourly/ daily/ weekly elevation in serum 
creatinine and blood urea nitrogen (BUN).26 
Different organisation such as acute dialysis quality initiative (ADQI), acute 
renal injury network (AKIN) and kidney disease international global outcome 
(KDIGO) have proved different definition for acute kidney injury. Among the definition 
of acute kidney injury (AKI) the most acceptable one is kidney disease international 
global outcome (KDIGO).27 
Acute kidney injury is may be any of the following,28 
• “Increase in serum creatnine (SCr) by  0.3mg/dl ( 26.5µmol/l) within 48 
hours” or 
• “Increase in serum creatinine to  1.5 times baseline, which is known or 
presumed to have occurred within the prior 7 days” or 
• “Urine volume < 0.5 ml/kg/h for 6 hours”. 
The incidence of acute kidney injury in the community is 2147 and 4085 per 
million populations per year (PMP) in developing and developed nations.29, 30 Recent 
reports in the developed world indicate that acute kidney injury is seen in 3.2 – 9.6 % 
of hospital admissions with overall mortality of 20%-50% in ICU patients.31, 32 Acute 
kidney injury demanding renal replacement therapy is 5-6% with a high in hospital 
mortality rate of 60%. It is estimated that nearly 2 million people die of acute kidney 
injury every year globally.33, 34 Those who survive acute kidney injury are at a greater 
risk for later development of chronic kidney disease (CKD). 
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The cause of acute kidney injury could be pre-renal, interensic renal and post 
renal ones. 
Pre-renal failure- It is the commonest form of acute renal failure, it is due to 
decrease in renal blood flow primarily as a result of hypovolemia. It is reversible if the 
cause of decreased renal blood flow can be identified and rectified before kidney 
damage occures. Pre-renal causes account for 40-70% of all acute kidney injury 
patients.35 
Interensic renal causes of AKI include diseases that affect the renal 
parenchyma which can be divided based on the compartment of the kidney that is 
affected like tubular injury, tubuloninterstitial disease, disease of the renal 
microcirculation and glomeruli and diseases of larger renal vessels. 
Post renal causes of AKI are diseases associated with urinary tract 
obstruction which account for 5% of renal failures.36 
2.2.1 DRUG INDUCED NEPHROTOXICITY IN HUMAN 
1. AMINOGLYCOSIDE INDUCED NEPHROTOXICITY 
Aminoglycosides preferentially affect the proximal tubular cells. These agents 
are freely filtered by the glomeruli and quickly taken up by the proximal tubular 
epithelial cells, where they are incorporated into lysosomes after first interacting with 
phospholipids on the brush border membranes. They exert their main toxic effect 
within the tubular cell by altering phospholipid metabolism. In addition to their direct 
effect on cells, aminoglycosides cause renal vasoconstriction. 
The two critical factors in the development of acute kidney injury (AKI) 
secondary to aminoglycoside Nephrotoxicity are dosing and duration of therapy. 
Aminoglycoside uptake by the tubules is a saturable phenomenon, so uptake is 
limited after a single dose. Thus, a single daily large dose is preferable to 3 doses 
per day. One dose per day presumably causes less accumulation in the tubular cells 
once the saturation point is reached.37, 38 
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2. AMPHOTERICIN B INDUCED NEPHROTOXICITY 
Amphotericin B binds to sterols in cell membranes, thereby creating pores 
that compromise membrane integrity and increase membrane permeability. It binds 
not only to ergosterol in fungal cell walls but also to cholesterol in human cell 
membranes; this is what accounts for its Nephrotoxicity. 
Characteristic electrolyte abnormalities include wasting of potassium and 
magnesium secondary to increased permeability of the cell membranes. The back-
leak of hydrogen ions in the collecting duct leads to distal renal tubular acidosis 
(dRTA).39, 40 
Lipid-based preparations of amphotericin B decrease but do not eliminate the 
Nephrotoxicity compared with traditional amphotericin B.41 This may be due to a 
direct nephrotoxic effect of the conventional preparation. 
3. CONTRAST-INDUCED NEPHROPATHY 
Although the pathogenesis of contrast-induced nephropathy (CIN) remains 
incompletely understood, it is most likely the result of renal vasoconstriction and 
direct renal tubular epithelial cell toxicity. Current theories regarding CIN toxicity 
include a combination of direct cytotoxicity with postischemic reperfusion injury 
resulting in oxygen free radical production leading to endothelial damage.42, 43 
4. CALCINEURIN INHIBITOR INDUCED NEPHROTOXICITY 
Cyclosporine and tacrolimus cause acute kidney injury (AKI) by inducing 
afferent and efferent arteriolar vasoconstriction. Persistent injury can lead to 
interstitial fibrosis. Tacrolimus has been shown to cause thrombotic microangiopathy 
as a result of endothelial injury.44, 45 
5. CISPLATIN INDUCED NEPHROTOXICITY 
Cisplatin usually affects the proximal tubules primarily with some secondary 
effect on the glomeruli and distal tubules. Cisplatin is excreted primarily in the urine, 
resulting in concentrated drug levels, which encourage uptake into the cells by 
passive diffusion or active uptake. Cisplatin is stable in the blood stream but 
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becomes hydrolyzed in the chloride-poor cellular environment. It is the hydrolyzed 
metabolite that binds DNA, RNA, proteins, and phospholipids, causing cytotoxicity.46 
MECHANISM OF CISPLATIN NEPHROTOXICITY
47
 
 
Fig.3: Pathways of Cisplatin-induced epithelial cell death 
Cisplatin enters renal epithelial cells via the OCT2 and, to a lesser extent, 
Ctr1 transporters. Cisplatin causes damage to nuclear and mitochondrial DNA and 
production of reactive oxygen species (ROS) which lead to activation of both 
mitochondrial and non-mitochondrial pathways of apoptosis and necrosis. 
Mitochondrial energetic are also disrupted by Cisplatin and may contribute to 
Nephrotoxicity. Fatty acids are the major source of energy for the proximal tubule, 
the primary site of Cisplatin kidney injury. Cisplatin inhibits fatty acid oxidation in rat 
kidney and in proximal tubule cells in culture through a reduction in PPAR- 
mediated expression of genes involved in cellular fatty acid utilization. 
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Fig.4: Pathways of Cisplatin-induced inflammation in renal cell 
Cisplatin-induced injury to renal epithelial cells causes release of DAMPs, 
which activate TLR4. Activation of TLR4 results in the production of a variety of 
chemokines and cytokines, including TNF- 
. These chemokines and cytokines up regulate adhesion molecules and 
attract inflammatory cells, such as neutrophils and T cells, into the region of injury. 
6. IFOSFAMIDE INDUCED NEPHROTOXICITY 
Ifosfamide is a known analog of cyclophosphamide. Although 
cyclophosphamide is not nephrotoxic, ifosfamide, by virtue of its metabolite 
chloroacetaldehyde, is toxic to the tubular cells, with preferential involvement of the 
proximal tubule leading to Fanconi syndrome.48, 49 
7. FOSCARNET INDUCED NEPHROTOXICITY 
Foscarnet, which is used to treat resistant cytomegalovirus (CMV) infections, 
causes acute interstitial nephritis and intra-tubular crystal formation. In addition to 
crystal formation, which can be made up of calcium salts or sodium salts, chelation 
of calcium by foscarnet leads to hypocalcemia.50, 51 
 
 
  REVIEW OF LITERATURE

DEPARTMENT OF PHRMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 

8. CRYSTAL-FORMING DRUG INDUCED NEPHROTOXICITY 
Sulfa drugs, acyclovir, methotrexate, ethylene glycol, and protease inhibitors 
like indinavir cause acute kidney injury (AKI) by tubular obstruction due to crystal 
formation in the tubular urine. 
Acyclovir may lead to the formation of intratubular crystals, which appear as 
birefringent needle-shaped crystals and can elicit an acute interstitial nephritis.52, 53 
9. RHABDOMYOLYSIS INDUCED NEPHROTOXICITY 
Rhabdomyolysis refers to the breakdown of skeletal muscle fibers, which 
leads to the release of potentially nephrotoxic intracellular contents into the 
circulation. Acute kidney injury (AKI) develops in this setting via the following  
3 mechanisms: 
• Renal vasoconstriction 
• Heme-mediated proximal tubular cell toxicity 
• Intratubular cast formation 
Heme proteins are believed to be involved in the generation of reactive 
oxygen species (ROS), which are known to cause tubular injury through peroxidation 
of membrane lipids and intracellular enzymes.54 
10. MULTIPLE MYELOMA INDUCED NEPHROTOXICITY 
Multiple myeloma causes renal failure by several mechanisms. The extra 
protein can be deposited in the kidney as amyloidosis or monoclonal immunoglobulin 
deposition disease affecting the glomeruli. Light-chain cast nephropathy occurs 
when light chains become concentrated in the tubular lumen. Plasma cells can 
infiltrate the kidney directly, causing kidney dysfunction. Hyper-calcemia can 
independently cause renal vasoconstriction. Volume depletion and medications used 
to treat multiple myeloma can also contribute to renal disease.55, 56 
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2.2.2 Kidney function test
57
 
There are a number of urine tests that can be used to assess kidney function. 
A small, randomly collected urine sample is examined physically for colour, odour, 
appearance, and concentration (specific gravity); chemically, for substances such a 
protein, glucose, and pH (acidity/alkalinity). 
 Glomerular function test: 
The entire clearance tests like Inulin, Creatinine, and Urea. 
 Tubular function test: 
Urine concentration or urine acidification test is used to determine tubular 
function. 
 Analysis of blood serum: 
• Serum Creatinine levels 
• Blood urea nitrogen (BUN) 
• Serum protein 
• Calcium 
• Magnesium 
• Phosphorus and 
• Uric acid 
 Analysis of urine: 
• Analysis of urea 
• Uric acid 
• Calcium 
• Oxalates 
• Magnesium 
• Phosphorus and 
• Citrate 
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Causes of chronic kidney disease may be seen on 
 Abdominal CT scan 
 Abdominal MRI 
 Abdominal ultrasound and Renal scan 
2.2.3 TREATMENT OF NEPHROTOXICITY
21 
The treatment plan for Nephrotoxicity may include: 
 Biopsy 
It is a procedure in which a needle is used to obtain small pieces of tissue 
from an organ for examination under different types of microscopes, each of which 
shows a different aspect of the tissue. 
 Dialysis 
It is the medical treatment that removes wastes and extra fluid from the blood 
after the kidneys have stopped working. 
 Immunosuppressant 
It is the medicine given to block the body's immune system. 
 Plasmapheresis 
It is a medical treatment in which the blood is treated outside the body to 
remove harmful antibodies, and then returned to the patient. 
2.2.4 PHARMACOLOGICAL THERAPY
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Although medicine cannot reverse chronic kidney disease, it is often used to 
help treat symptoms and complications and to slow further kidney damage. 
Medicines to treat high blood pressure 
Most people who have chronic kidney disease have problems with high blood 
pressure at some time during their disease. Medicines that lower blood 
pressure help to keep it in a target range and stop any more kidney damage. 
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Common blood pressure medicines include: 
 ACE inhibitors 
• Captopril 
• Zofenopril 
• Enalapril 
• Ramipril 
 Angiotensin II receptor blockers (ARBs) 
• Losartan 
• Vasartan 
• Candesartan 
• Telmisartan 
• Olmesartan 
 Beta-blockers 
• Propranolol 
• Metoprolol 
• Atenolol 
• Labetalol 
 Calcium channel blockers 
• Verapamil 
• Diltiazem 
• Nifedipine 
• Felodipine 
• Amlodipine 
• Benidipine 
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 Direct renin inhibitors 
 Diuretics 
• Furosemide 
• Spironolactone 
• Amiloride 
• Indapamide 
• Chlorthalidone 
• hydrochlorothiazide 
 Vasodilators 
• Minoxidil 
• Diazoxide 
• Hydralazine 
• Sodium nitroprusside 
Medicines to treat symptoms and complications of chronic kidney disease 
Medicines may be used to treat symptoms and complications of chronic 
kidney disease. These medicines include: 
 Erythropoietin (rhEPO) therapy and iron replacement therapy (iron pills or 
intravenous iron) for anemia. 
Medicines for electrolyte imbalances 
 Diuretics to treat fluid buildup caused by chronic kidney disease. 
 ACE inhibitors and ARBs. These may be used if you have protein in your 
urine (proteinuria) or have heart failure. 
Regular blood tests are required to make sure that these medicines don't 
raise potassium levels (hyperkalemia) or make kidney function worse. 
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Medicines used during dialysis 
 Both erythropoietin (rhEPO) therapy and iron replacement therapy may 
also be used during dialysis to treat anemia, which often develops in 
advanced chronic kidney disease. 
 Erythropoietin (rhEPO) stimulates the production of new red blood cells and 
may decrease the need for blood transfusions. This therapy may also be 
started before dialysis is needed, when anemia is severe and causing 
symptoms. 
 Iron therapy can help increase levels of iron in the body when rhEPO therapy 
alone is not effective. 
 Vitamin D helps keep bones strong and healthy. 
2.2.5 AYURVEDIC TREATMENTS OF NEPHROTOXICITY
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The Ayurvedic treatment of chronic renal failure is based on three principles: 
(i) Treating the damaged kidneys 
(ii) Treating the body tissues (dhatus) which make up the kidneys and 
(iii) Treating the known causes. 
2.2.5.1 TREATING THE DAMAGED KIDNEYS 
The damage done to the kidneys can be repaired using medicines like 
a) Punarnavadi Guggulu 
b) Gokshuradi Guggulu 
c) Gomutra Haritaki 
d) Chandraprabha Vati and 
e) Punarnavadi Qadha (decoction). 
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Herbal medicines useful in this condition are: 
i. Punarnava (Boerhaavia diffusa) 
ii. Gokshur (Tribulus terrestris) 
iii. Haritaki (Terminalia chebula) 
iv. Neem (Azadirachta indica) 
v. Daruharidra (Berberis aristata) and 
vi. Patol (Tricosanthe dioica). 
2.2.5.2 TREATING THE BODY TISSUES (DHATUS) WHICH MAKE UP THE 
KIDNEYS 
According to Ayurveda, the kidneys are made up of the "Rakta" and "Meda" 
dhatus. Treating these two dhatus is also an effective way to treat the kidneys. 
Medicines used are: 
 Patol 
 Saariva 
 Patha (Cissampelos pareira) 
 Musta (Cyperus rotundus) 
 Kutki (Picrorrhiza kurroa) 
 Chirayta (Swertia chirata) 
 Guduchi (Tinospora cordifolia) 
 Chandan (Santalum album) and 
 Shunthi (Zinziber officinalis). 
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2.2.5.3 TREATING THE KNOWN CAUSES 
Lastly, the known cause of chronic renal failure is treated using medicines 
which also act upon the kidneys. Vascular (related to the blood vessels) diseases 
like renal artery stenosis and inflammation of the artery walls (vasculitis) can be 
treated using medicines like 
i. Arogya Vardhini 
ii. Tapyadi Loha 
iii. Mahamanjishthadi Qadha 
iv. Kamdudha Vati 
v. Manjishtha (Rubia cordifolia) 
vi. Bhrungraj (Eclipta alba) 
vii. Saariva, Kutki and 
viii. Sarpagandha (Rauwolfia serpentina). 
Primary glomerular diseases like membranous nephropathy and 
glomerlonephritis can be treated using 
• Punarnava 
• Gokshur 
• Saariva and 
• Manjishtha. 
Secondary glomerular disease resulting from diabetes, systemic lupus 
erythematosus, rheumatoid arthritis etc. can be treated accordingly, using the 
medicines appropriate for those diseases. Similarly, suitable Ayurvedic medicines 
can be given for other causes like polycystic kidneys, prostate enlargement and 
neurogenic bladder. 
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2.2.5.4 ADVANTAGES OF AYURVEDIC MEDICATIONS 
The advantage of using Ayurvedic medicines in chronic renal failure is that in 
most patients, the kidney damage can be either partly or fully reversed, the 
frequency of dialysis can be reduced, and the increased risk of death from 
cardiovascular diseases can be significantly reduced. Thus, Ayurvedic medicines 
have the potential for an important therapeutic contribution in all the stages of this 
condition. 
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2.3 HERBAL PLANTS USED IN NEPHROTOXICITY 
Herbal Plants have the ability to synthesize a wide variety of chemical 
compounds that are used to perform important biological functions and to defend 
against attack from predators such as insects, fungi and herbivorous mammals. 
Many of these photochemical have beneficial effects on long-term health when 
consumed by humans and can be used effectively treat human disease. 
Pharmacologists, microbiologists, botanists and natural-product chemists are 
combing the earth for phytochemicals and leads that could be developed for the 
treatment of various diseases. In fact, according to the World Health Organization, 
approximately 25% of modern drugs used in the United States have been derived 
from plants. 
Numbers of medicinal plants show Nephroprotective activity and thereby play a 
vital role in the prevention and treatment of nephrtoxicity. 
Table-1 List of plants used Nephroprotective activity 
SI 
no. 
Botanical 
name 
Family 
Part 
used 
Extract 
used 
Method off 
inducing 
nephro-
toxicity 
R
e
fe
r
e
n
c
e
 
1 Aerva lanata Amaranthaceae 
Whole 
plant 
Aqueous 
Extract 
Gentamicin 60 
2 
Azima 
tetracantha 
Salvadoraceae Root 
Ethanolic 
extract 
Glycerol 61 
3 
Barringtunia 
acutangula 
Barringtoniaceae 
Whole 
plant 
Methanol- 
dichloromet
hane 
Gentamicin 62 
4 
Boerhaavia 
diffusa 
Nyctaginaceae Root 
Ethanolic 
Extract 
Ethylene 
glycol 
63 
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5 
Croton 
zambesicus 
Euphorbiaceae Root 
Ethanolic 
extract 
Gentamicin 64 
6 
Indigefera 
tinctoria 
Fabaceae 
Root 
and 
leaves 
Aqueous 
extract 
Cisplatin 65 
7 
Oroxylum 
indicum 
Bignoniaceae 
Whole 
plant 
Methanol- 
dichloromet
hane 
Gentamicin 62 
8 
Solanum 
xanthocarpum 
Solananaceae Fruit 
Ethanolic 
extract 
Gentamycin 66 
9 
Tamarindus 
indica 
Fabaceae Leaves 
Methanolic 
extract 
Gentamicin 67 
10 
Tribulus 
terrestris 
Zygophyllaceae Fruit 
Dried 
powder 
Gentamicin 63 
11 Vitex negundo Verbanaceae Root 
Methanol- 
dichloromet
hane 
Gentamicin 62 
12 
Volveriella 
volvacea 
Pluteaceae 
Cultuer
ed 
myceliu
m 
Aqueous- 
ethanolic 
extract 
Doxorubicin 68 
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2.4 EXPERIMENTAL DESIGN 
A number of models are used for the study of Nephroprotective activity. An 
appropriate experimental nephrotoxic model is of importance for studying the 
pathogenesis of Nephrotoxicity, evaluating the relative importance of various 
nephrotoxic factors and assessing the efficacy of different drugs in 
nephroprotectivity.69 
Sixteen models are used for inducing Nephrotoxicity in rats, they are: 
1) Glycerol-induced acute renal failure. 
2) Ischemia-reperfusion-induced acute renal failure. 
3) Gentamicin-induced acute renal failure. 
4) Cisplatin-induced acute renal failure. 
5) Radiocontrast media-induced acute renal failure.  
6) NSAID-induced acute renal failure. 
7) Osmosis-induced acute renal failure. 
8) Ifosfamide-induced acute renal failure. 
9) Uranium-induced acute renal failure. 
10) Mercuric chloride-induced acute renal failure. 
11) Potassium dichromate-induced acute renal failure. 
12) Folic acid-induced acute renal failure. 
13) Ferric-nitrilotriacetate-induced acute renal failure. 
14) S-(1,2-dichlorovinyl)-L-cysteine-induced acute renal failure. 
15) Sepsis-induced acute renal failure. 
16) Bipyridyls-induced acute renal failure. 
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1. Glycerol-induced acute renal failure 
Glycerol-induced ARF is characterized by myoglobinuria, tubular necrosis70 
and enhanced renal vasoconstriction. The pathogenic mechanisms involved in 
glycerol-induced renal failure include ischemic injury, tubular Nephrotoxicity caused 
by myoglobin, and the renal actions of cytokines released after rhabdomylosis.71,72 
The large numbers of disorders known to cause rhabdomyolysis include intrinsic 
muscle dysfunction (including trauma, burns, intrinsic muscle disease, and excessive 
physical exertion), metabolic disorders, hypoxia, drugs, toxins, infections, 
temperature extremes and idiopathic disorders.73 Complications associated with 
rhabdomyolysis include disseminated intravascular coagulation, hyper kalemia and 
other metabolic imbalances, ARF and acute cardiomyopathy. In general, about  
10–40% of cases with rhabdomyolysis develop ARF and it accounts for  
2–15% of all cases of ARF. The model for studying this form of ARF is obtained in 
the rat by intramuscular injection of glycerol.74 There is enhanced generation of 
hydrogen peroxide in renal cortex in rats with glycerol-induced acute renal failure.  
A standard method of inducing renal failure is by intramuscular administration of  
50% glycerol, v/v (8 ml/kg, im).75 The required amount of glycerol is administered as 
a deep im injection equally distributed to both hind legs. Rats are deprived of food 
and water for 24 h before glycerol administration after which they were sacrificed for 
kidney function evaluation.76 Also, Vlahovic et al. induced ARF by administration of 
glycerol (50% v/v in saline) im at a dose of 10 ml/kg. Injection volumes were divided 
equally between two hind limbs. The rats were dehydrated 18 h prior induction of 
myoglobinuric renal injury and sacrificed 48 h after injection of hypertonic glycerol 
without any restriction of diet or water.77 Intramuscular injection of glycerol in the 
rabbit induces a model of ARF at a dose of 10 mg/kg that resembles the ARF 
caused by massive release of myoglobin in crush syndrome in humans.78, 79  
An intramuscular administration of single dose of 8 ml/kg of glycerol is the most 
appropriate animal model that clinically mimics the rhabdomyolysis-induced renal 
failure in humans. 
2. Ischemia-reperfusion-induced acute renal failure  
Under the circumstances such as ischemia and nephrotoxins, ARF is 
characterized by “acute tubular necrosis” with flattened epithelia and tubular dilation 
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and cast formation. In these conditions, the tubular damage and altered glomerular 
hemodynamics may coexist or even lead to each other.80 Although the detailed 
cellular and molecular mechanisms of cell injury and the subsequent recovery are 
not entirely known, yet, data from the previous studies have indicated that ARF may 
result from the necrosis and apoptosis of renal epithelial cells.81, 82, 83 In the kidney, 
ischemia reperfusion injury is associated with cell death of tubular epithelial cells, 
localized in the stripe between the cortex and medulla; via necrosis or apoptosis that 
in-turn depends on the severity of the ischemic insult. Experimentally, ARF is 
induced by clamping the left renal artery for 1 h followed by reperfusion in 
anesthetized uninephrectomized dogs and renal failure is noted to develop within  
3 h.84 Bhalodia et al. have reported the development of renal failure in rats within 24 
h by clamping of both the kidneys for 60 min followed by 24 h of reperfusion.85, 86 The 
development of I/S-induced ARF in rats has also been demonstrated by unilateral 
left renal artery clamping using a small non traumatic vascular clamp for 45 min 
followed by reperfusion for 24 h.87,88 Foglieni et al. have reported the development of 
renal failure in rats by clamping both right renal artery and vein for 60 min with a 
microsurgical clamp followed by reperfusion for 60 min.89 Baker et al. have reported 
the development of renal failure in pigs by occluding infra-renal aorta with a standard 
angled arterial cross-clamp (palpation of distal aorta to confirm total aortic occlusion) 
for 150 min followed by reperfusion for 180 min.90 Matthijsen et al. have reported the 
development of I/R-induced renal failure in mice by applying a non traumatic 
vascular clamp to the left renal pedicle for 40 min after 1.0 cm long midline 
abdominal incision to induce ischemia followed by reperfusion for 24 h.91 Similarly, 
Susa et al. have reported the development of renal failure in mice by occluding left 
renal artery by an atraumatic microvascular clamp to induce ischemia lasting for  
25–37 min with reperfusion of 24 h.92 The ischemia of 45 min followed by 24 h 
reperfusion is more suitable and commonly used animal model to simulate the 
hemodynamic changes-induced alteration in renal function in humans. 
3. Gentamicin-induced acute renal failure  
In humans, gentamicin has been used for the treatment of life threatening 
Gram negative infections. Clinically, the high dose of gentamicin (2.5 mg/kg, im 
every 12 h for 7 days) has been shown to produce Nephrotoxicity.93 It has been 
reported that 30% of patients treated with gentamicin for more than 7 days show 
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signs of Nephrotoxicity.94 Gentamicin Nephrotoxicity is one of the most common 
causes of ARF and promotes both increased morbidity and greater health care 
costs. The clinical trial reports of elder patients have documented that 
aminoglycosides levels above 2.5µg/ml possess the major risk factors for 
aminoglycoside-associated Nephrotoxicity.95, 96 The mechanism of renal failure is 
that the polycationic aminoglycoside gentamicin is prefrentially uptaken by proximal 
tubular cells of the Nephron by binding to negatively charged phospholipids on the 
brush border and is then quickly transferred to the transmembrane protein  
megalin.97 After internalization via endocytosis, the aminoglycoside is transported to 
the lysosome and tightly binds to acidic phospholipids in the lipid bilayer, causing 
reduced phospholipase activity and production of phospholipid metabolites. The 
ability of gentamicin to alter mitochondrial respiration has been well documented in 
reports of both in vitro and in vivo studies.98 Other factors that contribute to the 
pathogenesis of gentamicin Nephrotoxicity include generation of superoxide anion 
and hydroxyl radicals, alteration of anti-oxidant defense systems, depletion of 
reduced glutathione, Na+-K+-ATPase inhibition, opening of mitochondrial 
permeability transition pore and activation of renin-angiotensin system.99, 100, 101, 102 
Different methods have been employed to induce renal failure in rats that include ip 
administration of gentamicin sulfate at a dose of 100 mg/kg/day (in 0.9% NaCl) for 
5–8 days and assessment of renal failure assessed 24 h after the last gentamicin 
injection.103 Xie et al. reported the development of ARF in rats by administration of 
relatively higher dose of gentamicin sulfate at the dose of 150 mg/kg, sc route for five 
days.104 On the other hand, in another variation, the development of ARF in rats has 
been shown by administrating gentamicin at a dose of 200 mg/kg twice daily for four 
consecutive days.105 Volpini et al. have reported the development of ARF in rats by 
administration of gentamicin at a dose of 40 mg/kg, im, twice a day for nine days,106 
while Bledsoe et al. reported the development of ARF in rats by administration of 
gentamicin at a dose of 80 mg/kg, sc for ten days with the assessment of renal 
failure on the eleventh day.107 The administration of gentamicin 100 mg/kg, ip, for  
5 consecutive days inducing renal dysfunction is more commonly used model and 
closely mimics the antibiotic-induced changes in renal function in clinical setup. 
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4. Cisplatin-induced acute renal failure  
Cisplatin [cis-diaminedichloroplatinum(II)], an anticancer drug, is broadly used 
for the therapy of cancers such as ovarian, head and neck carcinomas, and  
germ cell tumors. Nephrotoxicity is frequent and is the major limitation in  
Cisplatin-based chemotherapy. In humans, high dose of Cisplatin (75 mg/m2) has 
been used as baseline chemotherapeutic agent for the management of lung cancer. 
However, at this dose significant kidney damage has been seen in patients. The 
patients are administered saline infusion prior to and following Cisplatin  
(total of 3.5–4.0 liters during 3–4 h) to prevent Nephrotoxicity. The previous clinical 
studies had also reported that Cisplatin in a dosage of 20 mg/m2/day for 5 days 
causes significant changes in serum creatinine, creatinine clearance and 2.4 fold 
higher concentration of urine N-acetyl-b-D-glucosaminidase (an indicator of tubular 
damage) levels.108 There are several mechanisms that contribute to renal 
dysfunction following exposure to Cisplatin that include direct tubular toxicity in the 
form of apoptosis and necrosis that is mediated through inflammation, reactive 
oxygen species (ROS), calcium overload, phospholipase activation, depletion of 
reduced glutathione, inhibition of mitochondrial respiratory chain function, induction 
of apoptosis, opening of mitochondrial permeability transition pore (MPTP) and ATP 
depletion.109,110,111,112 Izuwa et al. have reported that administration of 5 ml/kg 
Cisplatin (0.1% of saline solution) in the abdominal cavity is associated with 
development of ARF in rats within 72 h of administration,113 while Roncal et al. 
reported the development of renal failure with the same dose of Cisplatin after five 
days of drug injection.114 Other reports have documented the development of renal 
failure with a single ip dose of 6 mg/kg,115 20 mg/kg and 30 mg/kg Cisplatin in rats 
within 72 h.116,117 The ARF model has also been developed in mice by injecting a 
single dose of Cisplatin 16 mg/kg, ip and renal dys-functioning has been observed 
after 72 h of injection.118 On the other hand, Lu et al. have reported the induction of 
ARF in mice by injecting Cisplatin at a dose of 30 mg/kg, ip.119 Other research 
groups have also developed Cisplatin-induced renal failure model in mice by varying 
the dose of Cisplatin that include 12 mg/kg, ip;120 18 mg/kg, ip;121 40 mg/kg, ip.122 
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5. Radiocontrast media-induced acute renal failure  
Clinically, radiocontrast media are very commonly used in radiology 
particularly for cardiac catheterization. Radiocontrast-induced nephropathy is a 
frequent clinical problem and is a major cause of acute renal failure.123 Patients 
administered with radiocontrast media have been reported to exhibit an increased 
frequency of clinical adverse events including permanent impairment of renal 
function, longer hospital stay and increased mortality rate. The incidence of 
radiocontrast nephropathy approaches 30–50% in patients with volume depletion, 
congestive heart failure, preexisting renal failure, or diabetes mellitus.124 In patients, 
isoosmolar radiocontrast (86% of iodixanol) and low-osmolar radiocontrast agent 
(14% of iohexol) induce acute renal failure.125 The pathogenesis of radiocontrast 
nephropathy appears to be multifactorial and includes a deleterious reduction of 
renal arteriolar blood flow and glomerular filtration rate as well as the direct renal 
tubular toxicity caused by the radiocontrast agents.126 The pathophysiology of toxic 
renal injury caused by radiocontrast media involves changes in generation of free 
radicals, inflammatory mediators, alteration of anti-oxidant defense systems and 
development of apoptosis.127 Different research groups have employed different 
contrast media to develop renal failure models in animals. Diatrizoate is a water-
soluble organic iodide contrast medium (1-deoxy-1-(methylamino)-D-glucitol-3,5-
diacetamido-2,4,6-triiodobenzoate).128 In the pure form, it contains 59.87% of 
organically bound iodine and 50% (w/v) solution contains 300 mg I/ml. It has an 
osmolality of 1550 mosm/kg, and is hypertonic to blood. Erley et al. have reported 
the development of ARF in rats by administration of sodium ditriazoate at a dose of  
2 ml/kg into the jugular vein over a period of 2 min. After the injection, three 
clearance periods are performed each lasting 30 min, in which urine and blood 
sampling is done to assess the renal failure.129 Yen et al. have reported the 
development of ARF in rats within 1 h by administration of 10 ml/kg of ditriazoate 
with an iodine load of 3700 mg/kg via the tail vein130 while Colbay et al. reported the 
development of ARF in rats within 24 h by iv injection of ditriazoate (7 ml/kg) over a 
period of 5 min.131  
Iohexol is commonly used as a non-ionic X-ray contrast media agent132 and 
for the measurement of GFR. Iohexol does not bind to serum proteins and is  
100% filtered through glomerulus, with no indications of tubular secretion or 
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reabsorption. Touati et al. have reported the development of renal failure in rats, in 
which rats were uninephrectomized and six days later, the aorta was clamped above 
the renal artery and a low-osmolar contrast media (CM), ioxaglate, was injected (1 
ml/min; 3 min) via an aortic puncture in the single remaining kidney. The parameters 
to assess the renal failure were determined 24 and 48 h after CM administration.133 
Lee et al. have reported the development of renal failure in mice within 24 h by ip 
administration of iohexol (350 mg iodine/ml, 1.5–3 g iodine/kg). Kwak et al. have 
reported the development of renal failure in rats by administering three doses of the 
contrast medium named Ultravist via iv route: low dose (CT: 0.5 ml/kg = 0.15 g 
iodine/kg), standard (CT: 2 ml/kg = 0.6 g iodine/kg), and high-dose  
(CT: 8 ml/kg = 2.4 g iodine/kg). The blood sampling was done 48 h after the contrast 
injection to assess the renal failure.134 Agmon et al. have reported the development 
of renal failure in rats by injecting sodium iothalamate (80%) through the arterial 
cannula over 2–3 min, at the dosage of 6 ml/kg. The blood samples were withdrawn 
24 h after the contrast medium injection to assess the renal impairment.135 Single 
dose administration of diatrizoate 7–10 ml/kg induced renal failure is more commonly 
used animal model to clinically simulate radiocontrast media-induced renal failure at 
the time of cardiac catheterization in patients. 
6. NSAID-induced acute renal failure  
Acetaminophen-induced acute renal failure  
Acetaminophen is most widely used in the world as an analgesic and antipyretic drug 
that is safe at therapeutic dosages. However, it is also known to cause hepatic 
necrosis and renal failure in humans136 and animals137 in overdoses. In human, 
acetaminophen represents a growing cause of renal failure in current medical 
practice. Acetaminophen-induced renal insufficiency is consistent with acute tubular 
necrosis, an increase in the plasma creatinine level and a decrease in the GFR. The 
cumulative doses of acetaminophen and aspirin have been documented to induce 
the renal failure at the dose of 100–499 g and 500–2,999 g or  3,000 g, 
respectively, in patients.138 Oxidative stress is reported to play a role in the 
pathogenesis of acetaminophen-induced renal damage whose metabolism occurs 
via cytochrome-P (CYP) 450 enzymes in both the liver and the kidneys. In renal 
tissues, prostaglandin synthetase and N-deacetylase enzymes play a key role in the 
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formation of free radicals and their metabolites. At higher doses, acetaminophen is 
shunted through these pathways leading to the increased production of reactive 
oxygen/nitrogen metabolites, gradual GSH depletion, formation of lipid peroxidative 
products leading to cell death and renal failure.139, 140, 141 Palani et al. reported the 
development of ARF in rats within 24 h by administrating a single dose of 
acetaminophen (750 mg/kg, p.o).142 Adeneye et al. and Cekmen et al. have reported 
the development of ARF within 24 h in rats by administration of a single dose of 
acetaminophen 800 mg/kg, ip, which was dissolved in normal saline.143, 144 Recently, 
Kheradpezhouh et al. have reported that ARF may be induced in rats within 18–24 h 
by ip administration of a single dose of acetaminophen (700 mg/kg), dissolved in 
propylene glycol and distilled water (50:50).145 Acetaminophen is also used to induce 
ARF in mice, as Li et al. have reported the development of ARF within 16 h in mice 
by administration of a single nephrotoxic dose of acetaminophen (600 mg/kg, 
dissolved in saline, 25 ml/kg, ip).146 In another study, Chen et al. have reported the 
development of ARF within 4 h in mice with different age groups, i.e., young ones 
with age of 3–31 month and old ones with age of 30–31 months, by administration of 
the same dose of acetaminophen (375 mg/kg, ip) dissolved in  
ethanol: propylene glycol (1:4).147 Single dose administration of acetaminophen 
(600–750 mg/kg) induced renal failure in rodents closely related to renal dysfunction 
due to overdose of acetaminophen in humans. 
Diclofenac sodium-induced acute renal failure  
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common 
prescription medicines and diclofenac is widely used NSAID for the management of 
pain and inflammation associated with arthritis. Unfortunately, one of the main side 
effects of NSAIDs administration is renal function damage.148 Therefore, the 
research has been directed for exploring non-steroidal analgesics that do not exhibit 
the typical side effects associated with NSAIDS including renal failure.149 In human, 
diclofenac has been widely used NSAID for the management of pain and 
inflammation associated with arthritis.150 A clinical trial report has documented that 
diclofenac (75 mg/day for six months) induces severe renal injury.151 NSAIDs 
mediated abrogation of prostaglandin synthesis and resultant renal ischemia is the 
major mechanism and intra-renal ROS generation is also potential mechanism 
contributing to development of acute interstitial nephritis. Experimentally,  
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ip administration of diclofenac (15 mg/kg) injection for 3 day has been reported to 
induce renal failure in rats.152 
7. Osmosis-induced acute renal failure  
Osmotic nephrosis is described on the morphological basis and is 
characterized by vacuolization and swelling of the renal proximal tubular cells. 
Clinically, osmotic nephrosis is due to intravenous infusion of hypertonic sucrose, 
hydroxyethyl starch, dextrans, and contrast media to reduce intra-cranial pressure.153 
In preclinical studies, osmotic diuresis is produced by administering 20% sucrose 
solution in rabbits that produces renal failure within the hour, and is characterized by 
vacuolar degeneration and nuclear shrinkage of tubular cells.154 Zhang et al. have 
reported that single dose administration of mannitol (4%, 9%, 19% and 27%) with 
dose of 5 ml/kg leads to induction of renal apoptosis and acute renal damage in 
spontaneous hypertensive rats.155 
8. Ifosfamide-induced acute renal failure  
Ifosfamide (IFO), a synthetic analog of cyclophosphamide, is an alkylating 
oxazaphosphorine and is widely used as first-line combination therapy for a variety 
of malignancies including metastatic germ-cell testicular cancer and some 
sarcomas.156 High-dose chemotherapy using IFO leads to hemorrhagic cystitis, 
Fanconi syndrome and ARF. Ifosfamide has been documented to induce the renal 
failure in patients at higher cumulative doses of 73.5 g/m2.157 The other clinical trial 
report has documented that cumulative ifosfamide dose of 9–128 g/m2/course 
induces severe renal failure in pediatric osteosarcoma patients.158 In another study, 
ifosfamide dose of 12 g/m2 for 6 consecutive days has been shown to develop 
Nephrotoxicity in 45.46% of patients that required hemodialysis and subsequently 
36.36% of patients were reported to die.159 IFO mustard reacts with deoxyribonucleic 
acids (DNA) molecules to form intra-and inter-strand cross-links, causing the DNA 
strand to break and ultimately cell apoptosis and/or necrosis.160, 161 Ifosfamide has 
also been shown to inhibit glutathione synthesis, generate reactive oxygen species, 
mitochondrial damage and apoptosis leading renal failure.162 Chloroacetaldehyde 
(CAA, a metabolite of ifosfamide) causes depletion of protein thiol and mitochondrial 
ATP, DNA cross-links and inhibition of DNA synthesis.163, 164 Badary has 
demonstrated that ip administration of ifosfamide at a dose of 50 mg/kg for  
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5 consecutive days induces the renal damage in rat.165 ARF has been shown to 
develop in mice by ip injection with different range of doses such as 350, 550, 800 or 
1100 mg/kg of ifosfamide. However, the dose of 550 mg/kg of ifosfamide was 
reported to produce reproducible ARF within 72 h. Single dose administration of 
ifosfamide, 550 mg/kg, ip, induced renal failure in more commonly employed animal 
model to study various aspects of renal dysfunction due to anticancer agents 
induced renal failure in cancer patients. 
9. Uranium-induced acute renal failure  
The kidney is being particularly sensitive to uranium. In chronically exposed 
uranium workers, the reduction in renal proximal tubular reabsorption of amino acids 
and low molecular weight proteins consistent with uranium nephrotoxicants has been 
reported.166 Uranium Nephrotoxicity has been extensively studied in experimental 
animals using uranyl nitrate (UN) and uranyl acetate, and is characterized by an 
increased serum creatinine and blood urea nitrogen (BUN) accompanied by 
abnormal electrolyte excretion, proteinuria, glucosuria and tubular necrosis.167 As 
with many nephrotoxins, uranyl-mediated pathologic damage is most evident in the 
straight position of the proximal tubule.168 Avasthi et al. reported the development of 
renal failure in rats by iv administration of two doses of uranyl nitrate 15 mg/kg and 
25 mg/kg.169 Later, researchers have reported the development of renal failure in 
rats within 5 days by ip administration of single dose of uranyl nitrate (0.5 and 10 
mg/kg) dissolved in 0.9% of saline.170, 171 Fleck et al. reported the development of 
renal failure in rats by administration of single dose of uranyl nitrate (5 mg/kg, ip) 
which was dissolved in 0.9% NaCl.172 It has been reported that single injection of  
1 ml/kg (5 mg/kg) into the tail vein of rat induces renal failure.173, 174 The plasma 
levels of urea nitrogen and creatinine increase significantly from third day to fifth day 
after intravenous administration of uranyl nitrate.175 Choi et al. have reported the 
development of renal failure in rats within 5 days by iv administration of uranyl nitrate 
at a dose of 5 mg/kg.176 Subcutaneous injection of uranyl acetate dihydrate  
(5 mg/kg) has also been reported to generate ARF within 72 h.177, 178 
10. Mercuric chloride-induced acute renal failure  
Mercuric chloride (HgCl2) is a well-known renal toxicant that causes ARF. A 
single injection of HgCl2 into rat results in necrosis of the tubular epithelial cells of the 
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kidney.179 Early tubular epithelial injury induced by mercuric chloride consists of 
fragmentation of the plasma membrane, swelling of the mitochondria and disruption 
of the nucleus and cytoplasmic organelles. Oxidative stress, which occurs after the 
metabolic generation of ROS, seems to play an important role in the pathogenesis of 
HgCl2-induced ARF.
180 Zimmermann et al. have reported the development of ARF in 
rat within 24 h by administration of a single sc injection of HgCl2 at a dose of 2.5 and 
4.7 mg/kg.181 Yoneya et al. have reported the development of ARF in rats within 24 h 
by ip administration of HgCl2 (1 mg/kg) dissolved in saline (1 mg/ ml).
182 Ewald et al. 
have also been reporting the development of ARF in mice within 24 h by 
administration of a single ip injection of HgCl2 at a dose of 6 mg/kg.
183 Ahn et al. has 
developed renal failure in rabbits within 24 h by administration of a single sc dose of 
HgCl2 at 10 mg/kg.
184 The development of ARF in rats within 24 h by administration 
of a single sc dose of HgCl2 at 4.0 mg/kg and 5.0 mg/kg has also been 
described.185,186 The administration of mercuric chloride 6 mg/kg, ip (single dose) in 
rabbit and 10 mg/kg, sc in mice (single dose) induced renal failure models more 
commonly used to clinically mimic the chemical industrial hazard associated with 
ARF in human. 
11. Potassium dichromate-induced acute renal failure  
Chromium is a naturally occurring element found in volcanic dust, rocks, soil, 
plants and animals. The most common forms of chromium in the environment are 
hexavalent (Cr6+) and trivalent (Cr3+). Cr6+ and Cr3+ are widely used in industrial 
and chemical processes such as leather tanning, printing, in hair dyes, steel 
manufacturing and wood preservative production. In some regions, waste disposal of 
chromium compounds to the environment contributes to increase its presence and 
potential toxicity.187 In biological systems, the soluble forms of Cr6+ are absorbed 
more easily than Cr3+ and are reduced to Cr3+ via Cr5+ by glutathione, ascorbate 
and hydrogen peroxide.188 Once chromium is absorbed, it is distributed in the liver, 
lung, spleen, kidney and heart. Appel et al. have reported the development of non-
oliguric pattern of ARF in rat within 24 h by administration of a single sc injection of 
potassium dichromate (K2Cr2O7) 15 mg/ kg.189 Recently, Khan et al. have 
demonstrated that a single injection of potassium dichromate (15 mg/kg, sc) causes 
development of ARF within 48 h.190 
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12. Folic acid-induced acute renal failure  
Folic acid (FA) induced ARF is a conventional animal model of human ARF.191 
FA-induced renal injury is associated with the rapid appearance of FA crystals within 
renal tubules and subsequent acute tubular necrosis, followed by epithelial 
regeneration and renal cortical scarring.192, 193 The molecular mechanisms by which 
FA induces ARF remain poorly understood. FA-induced renal failure is characterized 
by necrosis and apoptosis of tubular epithelial cells. In FA treated animals there is 
marked reduction in the expression of anti-apoptotic protein B-cell lymphoma-extra 
large (Bcl-xL) in kidneys along with marked elevation of tumor necrosis factor-a 
(TNF-a) in blood and kidneys. An iv injection of folic acid (250 mg/kg) is reported to 
induce ARF after 48 h in mice.194 
13. Ferric-nitrilotriacetate-induced acute renal failure  
Nitrilotriacetic acid (NTA), a synthetic chelating agent, is used as a household 
and hospital detergent in various countries. NTA is a low-toxic agent;195, 196 however, 
the ferric-nitrilotriacetate (Fe-NTA) complex causes acute Nephrotoxicity in animals 
as well as in humans.197 Fe-NTA-induced generation of free radicals, including 
superoxide anions and hydroxyl radicals, is a major mechanism of renal toxicity.198 
Hamazaki et al. have reported that the administration of single dose of Fe-NTA (15 
mg iron/kg) induces the acute tubular necrosis and renal failure in rats, while 
Umemura et al. reported that oral administration of Fe-NTA (12 mg Fe/kg) in rats 
causes ARF. Furthermore, administration of the single dose of Fe-NTA (8 mg 
iron/kg, ip) has also been reported to induce renal failure in rats. ARF is induced 
within 24 h in mice by ip injection of Fe-NTA with different doses such as 1, 2, and  
4 mg/kg.199 
14. S-(1,2-dichlorovinyl)-L-cysteine-induced acute renal failure  
S-(1,2-Dichlorovinyl)-L-cysteine (DCVC) is a potent nephrotoxicant and is a 
metabolite of trichloroethylene (TCE), a ground water contaminant listed as one of 
the most hazardous chemicals by Agency of Toxic Substances and Disease Registry 
(ATSDR).200 DCVC selectively damages the proximal tubules of the kidneys and 
causes mortality by ARF.201, 202 Administration of DCVC (30 mg/kg, ip) in mice is 
reported to cause loss of renal architecture within 24 h.203 Darnerud et al. have 
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reported that administration of single dose of DCVC at the lower dose of 5 mg/kg 
and higher dose of 25 mg/kg produces ARF in mice in a dose dependent manner. 
Administration of DCVC 5 mg/kg is reported to induce moderate lesions in the 
straight proximal tubules within 24 h. Furthermore, administration of 25 mg/kg of 
DCVC is documented to produce more pronounced lesions in the tubular segment 
that extend to other segments such as sub-capsular region. Wolfgang et al. have 
reported that two stereoisomers L-DCVC (at 10–5 M) and D-DCVC (at 10–5 M) 
produce renal injury in vitro system using rabbit renal cortical slices. Furthermore, 
administration of 25 mg/kg was also reported to produce ARF within 24 and 48 h in 
rabbits. 
15. Sepsis-induced acute renal failure  
Cecal ligation and puncture (CLP) induced polymicrobial sepsis is also 
employed to induce ARF in rats. The rats are anesthetized and a 2 cm ventral 
midline incision is made to expose and ligate the cecum with a 4.0 silk just distal to 
the ileocecal valve to avoid intestinal obstruction. Thereafter, ligated cecum is 
punctured three times with a 16 gauge needle followed by drainage with 3 mm wide 
latex slice twice and 5 mm width latex slice once. After this procedure, animals are 
fluid resuscitated with sterile saline (40 ml/kg) and within 24 h the animals develop 
renal failure as detected by an increase in creatinine levels along with extreme 
lethargy, diarrhea, piloerection and tachypnea.204 Ruetten et al. have demonstrated 
that intravenous infusion of lipopolysaccharide (LPS) (10 mg/kg) for 30 min in the the 
left femoral vein induces ARF in rat.205 Johannes et al. have reported that 30 min 
infusion of LPS (2.5 mg/kg) induces endotoxemia associated renal failure in rat.206 
Jesmin et al. have demonstrated that single ip injection of LPS derived from 
Escherichia coli (E. coli 055:B5) (15 mg/kg) induces the potential ARF in rats.207 
Recently, the renal artery occlusion along with sc injections of Escherichia coli in  
4 week old rats is reported to cause renal failure.208 An ip administration of bacterial 
toxic protein, i.e., LPS 15 mg/kg (single dose) induced renal failure in rats is more 
commonly employed animal model that mimics the infectioninduced renal failure in 
humans. 
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16. Bipyridyls-induced acute renal failure  
Paraquat and diquat dibromide are commercially available herbicides and are 
extensively used worldwide. Diquat is useful for studying the effects of ROS in vivo 
particularly in renal system.209 It stimulates cellular production of ROS by undergoing 
cyclic reduction-oxidation processes, in which the diquat dication is reduced to the 
monocation radical, which inturn reduces molecular oxygen to superoxide. Lock and 
Ishmael has demonstrated that administration of paraquat (680 µmol/kg, po, and 
108µmol/kg, sc) cause the renal tubular damage after 6 and 24 h, respectively, in 
rats.210 Diquat (680 µmol/kg, po)-induced renal tubular damage is characterized by 
urinary proteinuria and glucosuria within 6 to 24 h in rats. It has been reported that a 
single oral dose of diquat (540µmol/kg) induces the renal functional changes and 
kidney damage in rats.211 Rogers et al. have demonstrated that cumulative dose  
0–50 µmol/ kg of diquat ip during the period of 6 h induces the ARF in glutathione 
reductase - deficient mice, with the dose of 7.5 µmol/kg diquat, renal injury is mainly 
demonstrated in proximal tubules within 1 h and tubular necrosis is observed within  
2 hours. 
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2.5 CISPLATIN
212, 213 
Cisplatin, Cisplatinum, platamin, neoplatin, cismaplat or cisdiamminedichlorid
eplatinum (II) (CDDP) is a chemotherapy drug. It was the first member of a class 
of platinum-containing anti-cancer drugs, which now also includes carboplatin and 
oxaliplatin. These platinum complexes react in the body, binding to DNA and causing 
the DNA strands to crosslink, which ultimately triggers cells to die in a programmed 
way. 
Chemical structure 
 
 
 
Fig. No: 5 
 
Formula  : Cl2H6N2Pt 
Melting point  :  >270 °C 
Density  : 3.738 g/m3 
Molar mass  :  300.01 g/mol 
IUPAC ID  : (SP-4-2)-diammine dichloro platinum (II) 
 
SYNTHESIS  
The synthesis of Cisplatin starts from potassium tetrachloroplatinate. The 
tetraiodide is formed by reaction with an excess of potassium iodide. Reaction 
with ammonia forms K2[PtI2(NH3)2] which is isolated as a yellow compound. 
When silver nitrate in water is added insoluble silver iodide precipitates and  
K2 [Pt (OH2)2 (NH3)2] remains in solution. Addition of potassium chloride will form the 
final product which precipitates. In the tri-iodo intermediate the addition of the second 
ammonia ligand is governed by the trans effect. 
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USES 
Cisplatin is a widely used and highly effective cancer chemotherapeutic agent. 
Which is used to treat various type of cancers. One of the limiting side effects of 
Cisplatin use is nephrotoxicity. Research over the past 10 years has uncovered 
many of the cellular mechanisms which underlie Cisplatin-induced renal cell death. It 
has also become apparent that inflammation provoked by injury to renal epithelial 
cells serves to amplify kidney injury and dysfunction in vivo. 
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2.6 LIPOIC ACID (LA) 214 
 It is also known as -lipoic acid (ALA) and thioctic acid. It is an organosulfur 
compound derived from octanoic acid. -lipoic acid (ALA) is made in animals 
normally, and is essential for aerobic metabolism. It is also manufactured and is 
available as a dietary supplement in some countries where it is marketed as 
an antioxidant, and is available as a pharmaceutical drug in other countries. 
Chemical structure 
Fig. No: 6 
Formula  : C8H14O2S2  
IUPAC name  : (R)-5-(1,2-Dithiolan-3-yl) pentanoic acid 
Melting point  :  46–48 °C (115–118 °F; 319–321 K) 
Molar mass  :  206.33 g/mol 
 
Role of Lipoic acid in Cisplatin induced Nephrotoxicity
215 
Cisplatin treatment elevates Malondialdehyde (MDA) and declined reduced 
glutathione (GSH). And it will decreases catalase, superoxide dismutase (SOD) and 
Glutathione peroxidase (GPx) enzymes. 
Alpha lipoic acid (ALA) decreases the MDA and increases the GSH, catalase, 
SOD and GPx levels. Alpha lipoic acid (ALA) increases mRNA expression of 
catalase, CuZn SOD and GPx genes near to normal compared to Cisplatin-treated 
mice. Alpha lipoic acid (ALA) may play Nephroprotective role on Cisplatin-induced 
Nephrotoxicity through antioxidant and anti-apoptotic mechanisms combined with 
initiation of mRNA expression of antioxidant genes. 
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2.7 TAMARINDUS INDICA LINN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. no: 7  Plant of Tamarindus indica Linn with fruits and seeds 
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2.7.1 Plant monograph
216 
Botanical
 
classification 
 Kingdom  - Plantae 
 Sub kingdom  - Tracheobionta 
 Super division - Spermatophyta 
 Division  - Magnoliopsida 
 Sub class  - Rosidae 
 Super order  - Rosanae 
 Order   - Fabales 
 Family  - Fabaceae 
 Sub family  - Caesalpinioideae 
Genus  - Tamarindus Linn 
 Species  - T.indica 
 Tribe   - Detarieae 
Binomial name - Tamarindus indica Linn             
Synonyms 
 Tamarindus occidentails, Tamarindus officinalis hook, Tamarindus umbrosa 
salisb 
Biological source 
 Whole plant of Tamarindus indica Linn 
Family 
  Fabaceae / Caesalpinioideae 
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Vernacular names 
 Tamil  - Ambilam, Tindiruni, Puli 
 Sanskrit - Amla, Amli, Amlika, Tintiri 
 Telugu - Chinta, Chintapandu, Sinnta 
 Hindi  -  Ambli, Imli 
 Kannada - Amla, Amli, Gotu, Hunase, Hannu, Hunise mara 
 Malayalam - Amlam, Madhurappuli, Puli 
           English - Indian date, Sweet tamarind, Tamarind 
Parts used 
 Fruit pulp 
Geographical Distribution 
 Tamarindus indica Linn (family - Fabaceae) is distributed in Africa, America, 
Mexico, Asia and Arabian countries. 
Morphology 
Habitat 
 It is a large, slow growing, long living ever green tree with a trunk of diameter 
up to 1.5 -2.0 meter.  
 It can grow 20 – 30 meter height. 
 Bark is brown-gray coloured. 
 It can tolerate diversity of soils like loam, sandy and clay soil. 
 Slightly acidic soil is best for its growth. 
Foliage 
 Leaves are elliptical ovular, alternate, pinnate with reticulate venation. 
 It is a mass of bright green, dense foliage with feathery appearance. 
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 During hot season the leaf may be shed briefly in dry areas. 
 Leaves are 7.5 – 15 cm length, each having 10 to 20 pairs of oblong leaflets 
(1.25 – 2.5 cm) and 5 – 6 mm wide. 
 Leaves fold in cold damp weather and after sunset, due to the degeneration of 
lupeol in dark, which is synthesized in light. 
Flowers 
 The flowers are inconspicuous, inch-wide, five-petal and are borne in small 
racemes and are yellow with red streaks. 
 Due to the outer colour of the four sepals the flower buds pink, and which are 
shed when the flower opens. 
Fruits 
 Fruits are usually between 5 – 14 cm in length and approximately 2 cm 
wide. 
 It is an indehiscent legume, with a hard, brown shell called pods. 
 Along with the new branches, there is abundant growth of irregularly 
curved pods. 
 On maturation of pod, the flesh becomes brown or reddish brown and is 
filled with somewhat juicy, acidulous pulp. 
 Fruit ripe fully, the shells are brittle and easily broken. 
 The pulp has pleasing sweet or sour flavor along with high content of acid 
and sugar. 
 It is also rich in vitamin B and calcium content. 
 The pulp dehydrates to a sticky paste, enclosed by a few course strands of 
fibres. 
 The pods may contain 1 – 12 large flat, glossy brown, obviate seeds 
embedded in the brown, edible pulp. 
 Asian types have longer pods with 6 – 12 seeds, while the African and 
west Indian types have shorter pods, containing only 3 – 6 seeds. 
Phytochemistry 
Preliminary phytochemicals study of Tamarindus indica have revealed 
presence of phenolic compounds, cardiac glycosides, mallic acid, tartaric acid,uronic 
acid, mucilage, pectin, arabinose, xylose, galactose and glucose. 
  PLANT MONOGRAPH

DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 


Tamarind plant shows the presence of various essential elements like arsenic, 
calcium, cadmium, copper, iron, sodium, manganese, magnesium, potassium, 
phosphorus, lead and zinc. 
The ethanolic extract of Tamarindus indica showed the presence of fatty acid, 
out of which 21 are saturated fatty acids such as n-heptadeconate, hexadeconic 
acid, n-nonadecanoate, etc. along with 11 unsaturated fatty acids such as 
nenodecenoic acid, 10-octadecenoic acid, heptadeconoate, etc 
Fruit pulp contains organic acids such as tartaric acid, acetic acid, citric acid, 
formic acid, mallic acid and succinic acid. And also the pulp shows the presence of 
high amounts of ascorbic acid, vitamin B1, B3, amino acids such as alanine, 
phenylalanine, proline, serine, leucine; volatile oils; pectin; proteins and fat. 
Pulp also contains alkaloids, glycosides, saponins, sesquiterpenes, 
flavonoids, tannins and phlobatannins.    
Traditional uses 
 The raped and un-raped fruits pulp mixed with milk, honey or lemon juice 
were used as laxative and constipation reliever.   
 The leaves and bark were used as wound healer. 
 Fresh fruits are used as antipyretic. 
 Fruit pulp and leaves are used as anti-malarial agent. 
 Flowers, leaves, bark and fruit pulps were used as aphrodisiac. 
 Fresh bark or stem used as abdominal pain reliever. 
 Fruit pulp with lemon or milk and leaf juice were used as anti diarrheal and 
anti-dysentry agent. 
 Bark and leaves are used as anti asthmatic and anti-tussive. 
 Leaves or fruits are used as anti-measles and against mumps. 
 Leaf and bark decoctions were used as hepato-protective. 
 Leaves are used as anti diabetic. 
 Fruits are used as antibacterial. 
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 Bark is used as anthelminitic. 
 Fruits were used as preservative. 
 Antiepileptic. 
 Antiemetic. 
 Antihypertensive. 
 Anti-stomachic, and 
 Nephroprotective. 
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2.7.2 Earlier works reported on Tamarindus indica Linn 
 Bibekananda mehar et al., 217 have done Evaluation of hepatoprotective and 
invivo antioxidant activity of Tamarindus indica Linn (fabaceae) seeds extracts 
in streptozotocin induced diabetic rats. Diabetis induced hepatic damage was 
evaluated by the serum markers such as SGOT, SGPT, ALP, Bilirubin. 
Further the effect of HAETIS and AETIS on oxidative stress was determined 
by the markers of oxidative stresses like Lipid peroxidation (LPO), 
Determination of super oxide dismutase (SOD), Determination of catalase 
(CAT), glutathione (GSH), were estimated in liver tissue. HAETIS and AETIS 
at a dose level of 100mg/kg and 200 mg/kg produce significant (P< 0.05) 
hepatoprotection by decreasing the activity of serum enzymes, bilirubin and 
lipid peroxidation, while they significantly increase the level of glutathione, 
super oxide dismutase (SOD) and catalase in a dose dependant manner. 
Histopathological studies supports the above finding results indicate that 
hydroalcoholic extracts of Tamarindus indica at 200 mg/kg showed more 
significant hepatic protection as compared to other extracts. 
 Narendar Koyagura et al, 218 have done Antidiabetic and hepatoprotective 
activities of Tamarindus indica fruit pulp in alloxan induced diabetic rats. The 
objective of this study was to investigate antidiabetic, hypolipidemic and 
hepatoprotective activity of ethanolic extract of Tamarindus indica fruit pulp in 
alloxan induced diabetic rats.   Animals were made diabetic by   injection of  
single dose of alloxan in three test groups and after that they were treated 
with ethanolic extract of fruit pulp of Tamarindus indica 300 and 500 
mg/kg/body weight orally and metformin 150 mg/kg body weight orally 
respectively for 14 days. Anti-diabetic activity was estimated by measuring 
serum glucose and lipid profile and hepatoprotective activity was measured by 
estimating serum liver enzyme levels and histopathological changes in liver 
tissues. Results were analyzed by One way ANOVA followed by Scheffe 
multiple comparison tests (p<0.01). The two dose levels of Tamarindus indica 
significantly altered alloxan induced changes in serum glucose, lipid profile 
and serum enzyme levels. But in liver histopathology, higher dose (500 
mg/kg) of plant showed complete regeneration whereas lower dose (300 
mg/kg) showed only partial improvement in liver histopathology profile. 
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Present study revealed that Tamarindus indica possesses anti-diabetic and 
hepato protective activity in alloxan induced diabetic rats. 
 Abubakar MG et al., 219 have done Acute toxicity and antifungal studies of 
ethanolic leaves, stem and pulp extract of Tamarindus indica. The acute oral 
toxicity studies of the pulp extract of Tamarindus indica at 3000mg/kg and 
5000mg/kg body weight of resulted in no mortality. This suggests that the 
LD50 is greater than 5000mg/kg body weight and can be classified as 
practically non-toxic and considered safe by the recommendations of World 
Health Organization (WHO) and Organization for Economic and Cultural 
Development (OECD). Antifungal activity of ethanolic extract of Tamarindus 
indica (leaves, stem bark and pulp) against A. niger, A.flavus and 
F.oxysporum was studied. The result showed a dose dependent increase in 
inhibition of growth of these organisms. Of the three plant part the stem bark 
did not inhibit growth of A. niger and slightly inhibited the growth of A.flavus 
and F.oxysporum. From this study we can conclude that the pulp and 
especially the leaves of Tamarindus indica could be a promising antifungal 
agent and the result confirms the use of this plant in traditional medicine for 
the treatment of fungal infections. 
 Prabhu K.H et al., 220 have done Eco-dyeing using Tamarindus indica L. seed 
coat tannin as a natural mordant for textiles with antibacterial activity. 
Tamarind seed coat tannin was extracted and its tannin class was 
determined. The extracted tannin was employed as a natural mordant alone 
and in combination with metal mordant namely copper sulphate for cotton, 
wool and silk fabrics and dyed using natural dyes namely turmeric and 
pomegranate rind. The colour strength, colour coordinates, wash and light 
fastness were evaluated and compared for all the three fabrics with and 
without mordanting. The pre-mordanted fabrics on dyeing gave better colour 
strength, wash and light fastness than those dyeing obtained without 
mordanting. The total phenolic content of the extract was calculated and 
minimum inhibition concentration was 1% against both the Staphylococcus 
aureus and Escherichia coli bacteria. The mordanted and dyed fabrics 
resulted in good antibacterial activity up to 20 washes, when natural mordant 
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was used along with 0.5% and 1% copper sulphate mordant and dyed with 
natural dyes. 
 Doughari J.H et al., 221 have done Antimicrobial Activity of Tamarindus indica 
Linn. To evaluate the scientific basis for the use of the plant, the antimicrobial 
activities of extracts of the stem bark and leaves were evaluated against some 
common gram negative and gram positive bacteria and fungi. The study also 
investigated the chemical constituents of the plant and the effect of 
temperature and pH on its anti microbial activity. The antimicrobial activity of 
the concentrated extracts was evaluated by determination of the diameter of 
zone of inhibition against both gram negative and gram positive bacteria and 
fungi using the paper disc diffusion method.    Results of the phytochemical 
studies revealed the presence of tannins, saponins, sesquiterpenes, alkaloids 
and phlobatamins and the extracts were active against both gram positive and 
gram negative bacteria. The activity of the plant extracts were not affected 
when treated at different temperature ranges (4oC, 30oC, 60oC and 100oC), 
but was reduced at alkaline pH. Studies on the minimum inhibitory 
concentration (MIC) and minimum bactericidal concentration (MBC) of the 
extracts on the test organisms showed that the lowest MIC and the MBC were 
demonstrated against Salmonella paratyphi, Bacillus subtilis and Salmonella 
typhi and the highest MIC and MBC was exhibited against Staphylococcus 
aureus. Tamarindus indica has broad spectrum antibacterial activity and a 
potential source of new classes of antibiotics that could be useful for 
infectious disease chemotherapy and control. 
 Debasis De et al., 222 have done Searching for anti-hyperglycemic 
phytomolecules through bioassay-guided solvent fractionation and 
subfractionation from hydro-methanolic (2:3) extract of Tamarindus indica 
Linn seeds in streptozotocin-induced diabetic rat. The study identified the 
most effective fraction and subfraction of hydro-methanolic extract (2:3) of the 
seed of Tamarindus indica Linn having anti-diabetic activity in rats with 
diabetes induced by streptozotocin (STZ). The effective fraction and 
subfraction of Tamarindus indica were subjected to an anti-diabetic study in 
STZ-induced diabetic rats at two dose levels, 100 mg/kg and 25 mg/kg body 
weight twice a day. Serum insulin, glycosylated hemoglobin, carbohydrate 
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metabolic enzymes, and transaminases were assessed and the 
histopathology of the pancreas was examined after 8 weeks of treatment and 
compared to the vehicle control. Treatment of n-hexane fraction at a dose of 
100 mg/kg twice a day for 56 days in STZ-induced diabetic rat resulted in a 
significant reduction in fasting blood glucose and glycosylated hemoglobin 
levels along with a rise in serum insulin and glycogen contents in hepatic and 
skeletal muscle in comparison to chloroform, ethyl acetate, or n-butanol 
fraction treated groups as well as the untreated diabetic group. The most 
antidiabetic activity of n-hexane fraction had been highlighted by the activities 
of hexokinase, glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, 
and lactate dehydrogenase in the liver, kidney, cardiac, and skeletal muscle in 
respect with groups treated with other fractions. Two subfractions, A and B, 
were obtained from the n-hexane fraction using petroleum ether, of which 
subfraction B was more bioactive considering the above biosensors and was 
comparable with glibenclamide, a standard antihyperglycemic drug. 
Chromatographic study by high performance thin layer chromatography 
focused on two components of subfraction B, P1 and P2 where P1 is 
predominant, conformed by high performance liquid chromatography. The 
dose of subfraction B was 25 mg/kg twice a day i.e., 1/4 dose of the n-hexane 
fraction. The n-hexane fraction and subfraction B of Tamarindus indica are 
free from hepatic and renotoxicity according to the study of serum 
transaminase. 
 Iain E.P et al., 223 have evaluated X-ray diffraction studies on the xyloglucan 
from tamarind (Tamarindus indica) seed. Oriented samples of the xyloglucan 
polysaccharlde from tamarind seed were examined using X-ray diffraction. 
Periodicities indexing on a spacing of 2.06 nm were observed along the chain 
direction. This value is twice that reported for cellulose and is commensurate 
with four j-1, clinked glucose residues. Flat, ribbon like, two fold helical models 
for the b- 1, Clinked polyglucose backbone, with two possible schemes for 
decoration with xylose and galactose side groups, are proposed. 
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 Samina kabir khanzada et al., 224 have studied chemical constituents of 
tamarindus indica medicinal plant in sindh. Thirty two fatty acids, two other 
compounds 9ß, 19-Cyclo-4 ß4, 4, 14, -trimethyl-5-cholestan3ß-ol, 24R-
Ethyl cholest-5-en, 3-ol and 12 essential elements viz., Arsenic, Calcium, 
Cadmium, Copper, Iron, Sodium, Manganese, Magnesium, Potassium, 
Phosphorus, Lead, and Zinc were isolated from Tamarindus indica medicinal 
Plant. Accumulation of Copper was the lowest in Tamarindus indica while 
Potassium present with highest accumulation. Total protein in Tamarindus 
indica was 7.5 to 6.6 %. 
 Oranuch Nakchat et al., 225 have done Tamarind seed coat extract restores 
reactive oxygen species through attenuation of glutathione level and 
antioxidant enzyme expression in human skin fibroblasts in response to 
oxidative stress. To investigate the role and mechanism of tamarind seed coat 
extract (TSCE) on normal human skin fibroblast CCD-1064Sk cells under 
normal and oxidative stress conditions induced by hydrogen peroxide (H2O2). 
Tamarind seed coats were extracted with boiling water and then partitioned 
with ethyl acetate before the cell analysis. Effect of TSCE on intracellular 
reactive oxygen species (ROS), glutathione (GSH) level, antioxidant enzymes 
such as superoxide dismutase (SOD), glutathione peroxidase (GPx) and 
catalase activity including antioxidant protein expression was investigated. 
TSCE significantly attenuated intracellular ROS in the absence and presence 
of H2O2 by increasing GSH level. In the absence of H2O2, TSCE significantly 
enhanced SOD and catalase activity but did not affected on GPx. Meanwhile, 
TSCE significantly increased the protein expression of SOD and GPx in H2O2-
treated cells. Conclusions: TSCE exhibited antioxidant activities by 
scavenging ROS, attenuating GSH level that could protect human skin 
fibroblast cells from oxidative stress. Our results highlight the antioxidant 
mechanism of tamarind seed coat through an antioxidant enzyme system. 
 Tahiry Ranaivoson et al., 226 have done Distribution, biomass and local 
importance of tamarind trees in south-western Madagascar. The multipurpose 
tamarind (Tamarindus indica L.) tree is important for people’s livelihood and 
considered as sacred in the Mahafaly region of south-western Madagascar. 
However, the ongoing over exploitation of this species has caused a decline 
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of tamarind trees. In this study, the species distribution, changes in tamarind 
biomass and the role of traditional taboos for the conservation of this species 
were determined to identify opportunities and constraints for its conservation 
and appropriate land management planning. Semi structured interviews (N 
=63) were conducted in 10 villages in the study region to obtain information 
regarding the utilization of tamarind trees. During field surveys, the diameter 
at breast height (DBH), height, wood volume and wood biomass were 
measured for already felled trees (N = 25). Additionally, 318 trees were 
inventoried by measuring their DBH, height and GPS location. Using high 
resolution satellite images from 2004/2005 and 2012 the crown areas of all 
tamarind trees in six village areas were identified. Allometric equations were 
established to predict their wood biomass from DBH, crown surface and wood 
volume. Tamarind trees are mainly used as supplementary food, as well as 
for traditional ceremonies, charcoal production and medicinal purposes. 
Altogether, 0.06–0.35 trees ha−1 were observed. A regression analysis yielded 
high coefficients of determination for the relationships between DBH and 
wood biomass (r2 = 0.98), DBH and crown area (r2 = 0.72), and crown area 
and wood biomass (r2 = 0.71). From 2004/2005 to 2012, wood biomass 
losses of 12%–90% were caused by charcoal production and slash and burn 
agriculture. The traditionally sacred status of the tree has become insufficient 
to secure its conservation in the Mahafaly region. 
 Pinar Kuru et al., 227 have done Tamarindus indica and its health related 
effects. Tamarindus indica belongs to the family Fabaceae, commonly known 
as Tamarind tree, is one of the fruit tree species that is used as traditional 
medicine. The aim of this article is to review the current literatue on health 
related effect of Tamarindus indica. Literature review about this plant was 
conducted between 2003 and 2014 through Pubmed and Google. Only the 
health related articles selected. Tamarind tree is found especially in the Indian 
subcontinent, Africa, Pakistan, Bangladesh, Nigeria and most of the tropical 
countries. It is preferred to be used for abdominal pain, diarrhea and 
dysentery, some bacterial infections and parasitic infestations, wound healing, 
constipation and inflammation. It is a rich source of most of the essential 
amino acids and phytochemicals, and hence the plant is reported to possess 
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anti-diabetic, antimicrobial, anti-venomic, antioxidant, antimalarial, cardio 
protective, hepatoprotective, antiasthmatic, laxative and anti-hyper lipidemic 
activity. Tamarindus indica has ameliorative effects on many diseases. It can 
also be preferred as a nutritious support for malnourished. 
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3. SCOPE OF THE PRESENT STUDY 
 Kidneys play an important part in the maintenance of our endocrine and  
acid-base balance, blood pressure, erythropoiesis etc. The main functions of kidney 
can be categorised as formation of urine, water and electrolyte balance and 
production of hormones and enzymes. Kidneys have some delicate tasks, especially 
when they have to deal with unwanted substances, which they have to clear from the 
system. 
Nephrotoxicity can be defined as renal dysfunction that arises as a direct 
result of exposure to external agents such as drugs and environmental chemicals. It 
has been known from many years that toxic metals and heavy metals have toxic 
effects on kidney by accumulating and producing broad spectrum of morphological 
and functional effects of kidney. A number of drugs like cisplatin and antibiotics 
including penicillins, cephalosporins, tetracycline, sulfonamides and amino 
glycosides are known to be potential nephrotoxins. 
 Several plants have reported which have nephroprotective activity. Selection 
of scientific and systematic approach to the biological evaluation of plant products 
based on their use in the traditional systems of medicine and the nature of active 
principles form the basis for an ideal approach in the development of new drugs from 
plants. Tamarindus indicia Linn plant is scientifically proved for its traditional usage 
as nephroprotective. 
In Ayurveda plants namely milk thistle, drum stick, ginger, tamarind are used 
as nephroprotective agent. The common active constituents present in these plants, 
responsible for nephroprotective activity is found to be   flavonoids, iso flavonoids, 
phenolic compounds like tannins etc. The active constituents present in Tamarindus 
indica  are flavonoids, phenolic compounds, cardiac glycosides, malic acid, tartaric 
acid, mucilage, pectin, arabinose, xylose, galactose, glucose and uronic acid. Also 
the antioxidants present in the plant interact with free radicals and may prevent the 
damage caused by them. 
 Literature survey has revealed that the plant of Tamarindus indica Linn is 
prescribed as a nephroprotective, an anti-emitic, an antihistaminic, an antimicrobial, 
an antifungal, an anti-melioidosis, a defluoridation activity, an analgesic, an anti 
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pyretic, an anti-inflammatory, an anti-viral, an anti-nematodal, a molluscicidal activity, 
an anti-diabetic and hypolipidemic, an anti-oxidant activity, a cytotoxic, an 
antivenom, a hepatoprotective, an anthelmintic, a laxative, but no scientific study has 
been reported regarding its nephroprotective activity on its fruit pulp. Hence the 
study was undertaken to investigate the nephroprotective activity of ethanolic extract 
of the fruit pulp of Tamarindus indica Linn. 
There is a growing interest of public in traditional medicine, particularly in the 
treatment of nephrotoxicity partly because of limited choice in the pharmacotherapy. 
Certain Indian Medicinal plants have been reported to exhibit protective effect of 
renal tissues against injuries. Since there are only few researches made on this field 
of nephroprotection, this present study of nephroprotective activity of  
Tamarindus indica will satisfy the research for better and cost effective 
nephroprotection. 
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4. AIM AND OBJECTIVES 
AIM 
 The present study was focused on the investigation of Nephroprotective 
activity of the ethanolic extract of fruit pulp of Tamarindus indica Linn on cisplatin 
induced nephrotoxicity in Wistar albino rats. 
OBJECTIVES 
The objectives of the present study were, 
1. Evaluation of Nephroprotective effect of EETI. 
2. Comparison of Nephroprotective effect of standard drug with toxic 
substance. 
3. Comparison of Nephroprotective effect of EETI with standard drug as well 
as toxic substance. 
4. Histopathological studies of all groups of animals to compare the 
histological damages. 
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5. PLAN OF WORK 
The plan of work for the study of Tamarindus indica Linn was carried out as follows: 
1. Literature review, identification, authentification and collection of Tamarindus 
indica Linn 
2. Preliminary phytochemical study 
  A) Preparation of extracts  
B) Qualitative phytochemical studies 
3. Pharmacological studies 
 Nephroprotective study of ethanolic extract of fruit pulp of Tamarindus 
indica Linn. 
 Estimations of  
a. General parameters 
• Urine volume 
• Body weight 
b. Serum biochemical parameters 
• Serum Creatinine level 
• Blood urea nitrogen (BUN) 
c. Urine biochemical parameters 
• Creatinine clearence 
d. Oxidative stress parameters 
• Malondialdehyde (MDA) 
e. Enzymatic antioxidant parameter 
• Superoxide dismutase (SOD) 
• Catalase (CAT) 
• Glutathione peroxidase (GPx) 
f. Non enzymatic antioxidant parameter 
• Reduced glutathione (GSH) 
4. Histopathology of kidney 
5. Statistical analysis and documentation 
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6. MATERIALS AND METHODS 
6.1 SELECTION OF THE PLANT 
The medicinal plant Tamarindus indica Linn (Family: Fabaceae) was selected 
for Nephroprotective activity based on the literature survey. 
6.1.1 Collection and authentication of the plant 
 The fruit pulp of Tamarindus indica Linn was collected from Valanchery, 
Kerala. The plant Tamarindus indica Linn belonging to the family of Fabaceae was 
identified and authenticated by Prof. Dr. A. Balasubramanian, Ph.D., Director of 
A.B.S botanical conservation, Research and Training centre, kaaripatti, Salem 
district, Tamilnadu-636 106. 
6.1.2 Shade drying and cutting of the fruit pulp 
 The fruit pulp of Tamarindus indica Linn were collected and shade dried at the 
room temperature and then cut it in to small pieces, which was used for the 
extraction for further studies. 
6.2 MACERATION 
Fresh fruit pulps of Tamarindus indica Linn were cut into small pieces, seeds 
were removed and air dried. The dried pieces of Tamarindus indica Linn fruit pulp, 
weighing 100 g, were soaked in 500 ml of 95% ethanol in a round bottom flask for 
about 24 hours. 
6.3 EXTRACTION  
 Extracting values of crude drug are useful for their evaluation, especially when 
the constituents of a drug cannot be readily estimated by any other means. Further, 
these values indicate the nature of the constituents present in a crude drug 
Ethanolic extract 
Solvent          -     Ethanol 
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The process of extraction was done by reflux condensation method using 
soxhlet apparatus at 60-80 ºC for 9 hours. The extract was concentrated by 
distillation apparatus till a syrupy consistency was obtained. Finally, the extract was 
put in a china dish and evaporated at40-60 ºC temperature in a water bath, 22 gms 
of semisolid extract was obtained.228  
Table-2 
Nature and colour of Ethanolic extract of Tamarindus indica Linn 
S. No Name of the plant extract Part used 
1. Tamarindus indica Linn Fruit pulp 
 
6.3.1 Preliminary phytochemical screening 
229, 230 
 The Ethanolic extract of the fruit pulp of Tamarindus indica Linn was 
subjected to a preliminary phytochemical screening to identify the active chemical 
constituents. 
Test solution  
 The Ethanolic extract of the fruit pulp of Tamarindus indica Linn was taken 
and dissolved in distilled water. 
6.3.1.1 TEST FOR CARBOHYDRATE 
 A small quantity of the extract was dissolved in 4 ml of distilled water and 
filtered. The filtrate was subjected to the following tests to detect the presence of 
carbohydrate and glycosides. 
Molisch’s test 
 Few drops of Molisch’s reagent were added to an aqueous solution of each 
extract followed by vigorous shaking. Thereafter, 1.0 ml of conc. H2SO4 was added 
carefully by sliding down the walls of the tube gently to form two layers. There is an 
appearance of brown ring separating the solution into two layers, it indicate the 
presence of carbohydrate. 
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Fehling’s test 
 To 1.0 ml of aqueous solution of each extract was added 3.0 ml of a mixture 
of equal volumes of Fehling’s solutions A and B and boiled in a water bath at about 
40 °C for 2 min. A brick red colour at the bottom of the test tube was an indication of 
the presence of reducing sugar. 
Anthrone test 
 2 mg of the extracts was shaken with 10ml water, filtered concentrated. To 
this 2ml of anthrone reagent solution was added. Formation of green or blue colour 
indicated presence of carbohydrates. 
6.2.1.2 TEST FOR GLYCOSIDES 
Tests for glycosides were performed as follows: 
(i) To 0.1 g of each extract in a test tube was added 5.0 ml of water and the 
mixture heated in a water bath at 100 °C for 2 min. The mixture was filtered through 
a Whatman No. 1 filter paper. A mixture of Fehling’s solutions A and B were added 
to the filtrate until it became alkaline: followed by heating for 2 min. 
(ii) The above procedure was repeated, except that 5.0 ml of dilute sulphuric 
acid was added to 0.1g of the extract instead of water: and the quantity of precipitate 
formed was noted. 
(iii) About 0.1 g of each extract was put into a stoppered conical flash in which 
was suspended a strip of sodium picrate paper. The flask was warmed gently for 
about an hour at 37 °C and allowed to stand. The test paper was examined for any 
change in colour. 
Legal’s and Borntrager’s tests 
 Another portion of the extract was hydrolysed with hydrochloric acid for a few 
hours on a water bath and then hydrolysate was subjected to Legal’s and 
Borntrager’s tests to detect the presence of different glycosides. 
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Legal’ test 
 To the hydrolysate, 1ml of pyridine and a few drops of sodium nitroprussside 
solutions were added and then it was made alkaline with sodium hydroxide solution. 
Appearence of pink to red colour showed the presence of glycosides. 
Borntrager’s test 
 Hydrolysate was treated with chloroform and then the chloroform layer was 
separated. To this equal of the diluted ammonia solution was added. Ammonia layer 
acquired pink colour, showing the presence of glycosides. 
6.2.1.3 TEST FOR TANNINS 
 Small quantity of the extract was taken in water and test for the presence of 
tannins was carried out with the following reagents. 
Ferric chloride test 
 A 5%solution of ferric chloride in 90% of alcohol was prepared. Few drops of 
this solution was added in to a little of the above filtrate. Dark green or deep blue 
colour is obtained, it indicate the presence of tannins. 
Lead acetate test 
 A 10% w/v solution of basic lead acetate in distilled water was added to the 
test filtrate. Precipitate is obtained, presence of tannins. 
Potassium dichromate test 
 If on an addition of solution of potassium dichromate in test filtrate, dark colour 
is developed, tannins are present. 
6.2.1.4 TEST FOR SAPONINS 
Presence of saponins was determined by their frothing property as well as 
capacity to form emulsion with oils. (i) For the frothing test, about 5 mg of extract was 
shaken vigorously with sodium bicarbonate and examined for frothing; (ii) For the 
emulsification test, 2 drops of olive oil was added to 5.0 mL of aqueous solution of 
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the extract in a test, shaken vigorously and observed for formation of an emulsion. 
The control was without extract but water and olive oil. 
Foam test 
 The extract was diluted with 20 ml of distilled water and it was agitated in a 
graduated cylinder for 15minutes. There is formation of one layer of foam, which 
showed the presence of saponins. 
6.2.1.5 TEST FOR FLAVANOIDS 
With aqueous sodium hydroxide solution 
 Small quantity of the extract was dissolved in aqueous sodium hydroxide. 
Yellow colour was produced which indicated the presence of flavones. 
With conc. sulphuric acid 
 To the small portion of extract, concentrated sulphuric acid was added. Yellow 
to orange colour was produced which indicated the presence of flavones. 
Shinoda’s test 
 Small quantity of the extract was dissolved in ethanol. To them pieces of 
magnesium were added followed by conc. hydrochloric acid drop wise added and 
heated. Appearance of magenta colour showed the presence of flavonoids. 
6.2.1.6 TEST FOR ANTHROQUINONES  
Approximately 0.1 g of the extract was mixed with 5.0 ml of chloroform and 
agitated for 5.0 min. The solution was filtered and equal volume of ammonia was 
added to the filtrate and agitated again. A brick red colour in the upper aqueous layer 
indicates the presence of free anthroquinones. 
6.2.1.7 TEST FOR ALKALOIDS 
Dragendroff’s test 
 To the extract Dragendroff’s reagent (potassium bismuth iodine solution) was 
added. A reddish brown precipitate was produced, which indicated the presence of 
alkaloids. 
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Mayer’s test 
 To the extract Mayer’s reagent (potassium mercuric iodine solution) was 
added. A reddish brown precipitate was produced, which indicated the presence of 
alkaloids. 
Wagner’s test 
To the extract Wagner’s reagent (iodine- potassium iodide solution) was 
added. A reddish brown precipitate was produced, which indicated the presence of 
alkaloids. 
Hagner’s test 
 To the extract Hagner’s reagent (Saturated solution of picric acid) was added. 
A yellow precipitate was produced, which indicated the presence of alkaloids. 
Tannic acid test 
 To the extract tannic acid solution was added. A buff colour precipitate was 
produced, which indicated the presence of alkaloids. 
6.2.1.8 TEST FOR PHYTOSTEROL AND TERPENES 
 A 1.0 g weight of the extract was mixed with 5.0 ml of 95% ethanol and then 
filtered. The filtrate was evaporated to dryness and the residue re-dissolved in 5.0 ml 
of anhydrous chloroform and then filtered. The latter filtrate was divided into two 
portions for the following tests: 
Liebermann-Burchard Test 
The first portion was mixed with 1 ml of acetic anhydride followed by the 
addition of 1.0 ml of concentrated Sulfuric acid gently down the side of the test tube 
to form a layer underneath. The formation of a reddish violet colour at the junction of 
the two liquids and a green colour in the chloroform layer would indicate the 
presence of terpenes. 
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Salowski’s Test 
To the second portion of the solution was added 2.0 ml of concentrated 
Sulfuric acid carefully down the side of the tube so that the sulfuric acid formed a 
layer. No reddish brown colour at the interface would indicate the absence of sterols. 
The results of phytochemical screening were shown in Table no.5 
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6.3 Pharmacological Evaluation 
6.3.1 ACUTE TOXICITY STUDY
231
 
 Whenever an investigator administers a chemical substance to a biological 
system, different types of interactions can occur and a series of dose-related 
responses result. In most cases these responses are desired and useful, but there 
are a number of other effects which are not advantageous. These may or may not be 
harmful to the patients. The types of toxicity tests which are routinely performed by 
pharmaceutical manufacturers in the investigation of new drug involve acute, sub-
acute and chronic toxicity. Acute toxicity is involved in estimation of LD50 (the dose 
has proved to be lethal (causing death) to 50% of the tested group of animals). 
Determination of oral toxicity is usually an initial screening step in the 
assessment and the evaluation of the toxic characteristics of all compounds. This 
article reviews the methods of so far utilized for the determination of median lethal 
dose (LD50) and the new changes which would be made. This has to go through the 
entire process of validation with different categories of substances before its final 
acceptance by regulatory bodies. 
Organisation for Economic co-operation and Development (OECD) regulates 
guidelines for oral acute toxicity study. It is an international organisation which works 
with the aim of reducing both the number of animals and the level of pain associated 
with acute toxicity testing. To determine the acute oral toxicity OECD frames the 
following guideline methods. 
 OECD 401 – Acute Oral Toxicity 
 OECD 420 – Acute Oral Toxicity: Fixed Dose procedure 
 OECD 423 –Acute Oral Toxicity: Acute Toxic Classic method 
 OECD 425 – Acute Oral Toxicity: Up and own Procedure 
In the present study the acute oral toxicity of Spermacoce ocymoides Burn f 
was carried out according to OECD 423 guideline (Acute Oral Toxicity: acute Toxic 
Classic Method). 
ACUTE ORAL TOXICITY 
 Acute oral toxicity refers to those adverse effects that occur following 
oral administration of a single dose of a substance or multiple doses given within 24 
hours. 
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LD50 (median lethal oral dose) 
LD50 (median lethal oral dose) is a statistically derived single dose of a 
substance that can be expected to cause death in 50 per cent of animals when 
administered by the oral route. The LD50 value is expressed in terms of weight of test 
substance per unit weight of test animal (mg/kg). 
PRINCIPLE 
It is based on a stepwise procedure with the use of a minimum number of 
animals per step; sufficient information is obtained on the acute toxicity of the test 
substance to enable its classification. The substance is administered orally to a 
group of experimental animals at one of the defined doses. The substance is tested 
using a step wise procedure, each step using three animals of a single sex (normally 
females). Absence or presence of compound- related mortality of the animals dosed 
at one step will determine the next step, i.e.; 
 
• No further testing is needed 
• Dosing of three additional animals, with the same dose 
• Dosing of three additional animals at the next higher or the next lower 
dose level. 
SELECTION OF ANIMAL SPECIES 
 The preferred rodent species was the rat. Normally females were used. 
Females were generally slightly more sensitive. Healthy young adult animals of 
commonly used laboratory strains were employed. Females were nulliparous and 
non-pregnant. Each animal, at the commencement of it’s dosing, were between 8 to 
12 weeks old. 
ADMINISTRATION OF DOSES 
 The test substance was administered in a single dose by gavages 
using a oral feeding needle. Animals were fasted prior to dosing (e.g. with the rat, 
food but not water should be withheld over-night, with the mouse, food but not water 
was withheld for 3-4 hours). Following the period of fasting, the animals were 
weighed and the test substance administered. After the substance has been 
administered, food was withheld for a further 3-4 hours in rats. 
 
 
  MATERIALS AND METHODS

DEPARTMENT NOF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 


OBSERVATION 
 Animals were observed individually after dosing at least once during 
the first 30 minutes, periodically during the first 24 hours, with special attention given 
during the first 4 hours, and daily thereafter, for a total of 14 days, except where they 
need to be removed from the study and humanely killed for animal welfare reasons 
or are found dead. However, the duration of observation was not fixed rigidly. It was 
determined by the toxic reactions, time of onset and length of recovery period and 
extended when considered necessary. The times at which signs of toxicity appeared 
and disappeared were important, when toxic signs were to be delayed. All 
observations were systematically recorded with individual records being maintained 
for each animal. 
Fixation of doses of the extract 
 An acute oral toxicity study was carried out according to OECD guidelines. No 
adverse effect was reported or mortality in albino wister rats up to 2000mg/kg p.o. of 
ethanolic extracts of Tamarindus indica Linn. 
 Therefore, the maximum tolerated dose 200mg/kg & 400mg/kg was chosen 
for further studies. 
6.3.2 Animals 
Albino wistar rats of either sex (150-200 gm) were procured from the animal 
house of King’s institute, Guindy, Chennai, Tamilnadu, India. Prior to the experiment 
the rats were housed in a clean polypropylene cage (6 rats/cages) for a period of 7 
days under temperature (25-300c), relative humidity (45-55%).
The Institutional Animal Ethics Committee approved the experimental protocol 
and the conditions in the animal house approved by Committee for Supervision on 
Experiments on Animals. The study was conducted in accordance with IAEC 
guidelines (IAEC approval No: IAEC/XLVIII/03/CLBMCP/2016 dated on 
04/05/2016).



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6.3.3 Drugs and chemicals 
 All the drugs, chemicals and reagents were procured from S.D Fine 
chemicals, Mumbai, India. All chemicals and reagents used were of analytical 
reagent. 
6.3.4 Experimental protocol
232 
The Nephroprotective activity was tested on five groups of albino wistar rats of 
either sex, each group consisting of six animals. 
  
 On the 10th day 2 hours after the administration of standard Nephroprotective 
drug (Lipoic acid) and Tamarindus indica (200 & 400 mg/kg) II-V groups received 
cisplatin (7.5mg/kg; i.p). 
6.3.5 Blood collection techniques used in the present study
232
 
 At the end of the experimental period, ie on the 15th day animals were 
sacrificed under mild ether anesthesia. The blood was collected by retro-orbital vein 
puncture using a fine capillary to an anticoagulant tube and allowed to stand for 30 
min at 37°C and then centrifuged to separate the serum to evaluate the biochemical 
markers. 
 
 
Group-I : Served as normal control received 0.5 % DMSO (Dimethyl 
sulphoxide)    ; for 15 days. 
Group-II : Served as Nephrotoxic control, received vehicle (0.5% DMSO); 
for 15 days. 
Group-III : Received the standard Nephroprotective drug, (Lipoic acid 
(50mg/kg;  p.o)) dissolved in DMSO for 15 days. 
Group-IV : Received ethanolic extract of Tamarindus indica Linn (200mg/kg; 
p.o) dissolved in DMSO for 15 days. 
Group-V : Received ethanolic extract of Tamarindus indica Linn (400mg/kg; 
p.o) dissolved in DMSO for 15 days. 
  MATERIALS AND METHODS

DEPARTMENT NOF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 


6.3.6 Preparation of kidney homogenate
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 The kidney was quickly removed and perfused immediately with ice-cold 
saline (0.9% NaCl). A portion of the kidney was homogenized in chilled Tris-HCl 
buffer (0.025 M, pH 7.4) using a homogenizer. The homogenate obtained was 
centrifuged at 5000 rpm for 10 minutes, supernatant was collected and used for 
various biochemical assays. 
6.4 ANALYIS OF GENERAL PARAMETERS 
6.4.1 Estimation of urine volume 
The animals are kept in separate metabolic cages for 24 hours. Each rat urine 
volume are taken after 24 hours. The food wastes and fecel matters are removed 
from the urine. And the volume of urine is measured by using measuring cylinder.  
6.4.2 Estimation of Body weight 
At the end of the experiment, each group of the animals were kept individually 
in the cages. Remove the food and water, and each animal are individually weighed 
and the weight were recorded. 
6.5 ANALYIS OF SERUM BIOCHEMICAL PARAMETERS 
6.5.1 Estimation of Serum Creatinine
233
 
 Five test tubes were labelled as A, B, C, D and E. Where A&B is taken as 
standard, C &D taken as test and the E where taken as blank. Into E (blank), 2 ml of 
distilled water, into C&D (test), 0.5 ml serum and 1.5 ml of water, into A&B 
(standard), 1.5 ml of water and 0.5 ml of creatinine standard (3mg/dl) were pipette 
out. 6 ml of picric acid and 0.4 ml of sodium hydroxide (NaOH) (2.5M) were added in 
all the five test tubes. 
Reagents 
1. Creatinine stock standard: 150 mg creatinine in 100 ml water (1.5 mg/ml) 
2. Creatinine working standard for serum (3mg/dl): dilute 10 ml of stock and 
make the volume up to 500 ml with water. 
3. Serum samples. 
4. NaOH (2.5 M). 
5. Picric acid. 
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Table-3 
 Standard (A,B) Test (C,D) Blank (E) 
Serum - 0.5 ml - 
Distilled water 1.5 ml 1.5ml 2 ml 
Standard for 
serum 
0.5 ml - - 
Picric acid 6 ml 6 ml 6 ml 
NaOH (2.5 M) 0.4 ml 0.4 ml 0.4 ml 
 
1. Mix well  
2. Add 0.4 ml of 2.5 M NaOH 
3. Allow to stand for 20 minutes 
4. Read the absorbance against the blank at 520 nm  
 
6.5.2 Estimation of Serum Blood urea nitrogen (BUN) 
234
 
The blood urea was estimated by Berthelot method (Fawcett and Scott, 1960) 
using the commercially available kit (Kamineni Life Sciences Pvt. Ltd. Hyderabad, 
India). 1000 µl of working reagent-I containing urease reagent, and a mixture of 
salicylate, hypochlorite and nitroprusside was added to 10 µl of serum, 10 µl of 
standard urea (40 mg/dl) and 10 µl of purified water to prepare test, standard and 
blank, respectively. All the test tubes were mixed well and incubated at 37 °C for  
5 min. Then 1000 µl of reagent-II containing alkaline buffer, was added to all the test 
tubes, which were incubated at 37 °C for 5 min. Urease catalyses the conversion of 
urea to ammonia and carbon dioxide. The ammonia thus released reacts with a 
mixture of salicylate, hypochlorite and nitroprusside to yield indo phenol, a blue-
green coloured compound. The intensity of the colour produced is directly 
proportional to the concentration of urea in the sample and is measured 
spectrophotometrically at 578 nm. The blood urea was calculated using the following 
formula: 
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6.6 ANALYIS OF URINE BIOCHEMICAL PARAMETERS 
6.6.1 Estimation of Creatinine clearance
235 
Five test tubes were labelled as A, B, C, D and E. Where A&B is taken as 
standard, C&D taken as test and the E where taken as blank. Into E (blank), 2 ml of 
distilled water, into C&D (test), 0.5 ml urine and 1.5 ml of water, into A&B (standard), 
1.5 ml of water and 0.5 ml of creatinine standard (3mg/dl) were pipette out. 6 ml of 
picric acid and 0.4 ml of sodium hydroxide (NaOH) (2.5M) were added in all the five 
test tubes. 
 
1. Creatinine stock standard: 150 mg creatinine in 100 ml water (1.5 mg/ml) 
2. Creatinine working standard for urine (0.75 mg/dl): dilute 50 ml of stock and 
bring the volume up to 200 ml with water. 
3. Urine samples. 
4. NaOH (2.5 M). 
5. Picric acid. 
Table-4 
 
 Standard A,B Test C,D Blank E 
Urine - 0.5 ml - 
Distilled water 1.5 ml 1.5ml 2 ml 
Standard for 
serum 
0.5 ml - - 
Picric acid 6 ml 6 ml 6 ml 
NaOH (2.5 M) 0.4 ml 0.4 ml 0.4 ml 
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1. mix well 
2. Add 0.4 ml of 2.5 M NaOH 
3. Allow to stand for 20 minutes 
4. Read the absorbance against the blank at 520 nm 
 
Creatinine clearance =  ×volume of urine ml/min/1.73 m
2 
 
 
 
6.7 ANALYIS OF OXIDATIVE STRESS PARAMETERS 
6.7.1 Estimation of malondialdehyde (MDA)
236
 
            Lipid peroxidation (LPO) was assayed by the method of in which the 
malondialdehyde (MDA) released served as the index of LPO. The extent of LPO in 
the hepatic tissue was assayed by measuring one of the end products of this 
process, the thiobarbituric acid-reactive substances (TBARS). As 99% TBARS is 
malondialdehyde (MDA), thus this assay is based on the reaction of 1 molecule of 
MDA with 2 molecules of TBARS at low pH (2- 3) and at a temperature of 95°C for 
60 min. The resultant pink chromogen can be detected spectrophonometrically at 
532 nm. 
Reagents 
 Standard: 1, 1, 3, 3-tetra ethoxypropane (TEP). 
 8.1% Sodium dodecyl sulphate (SDS) 
 20%Acetic acid 
 0.8%Thiobarbituric acid (TBA)  
 15:1 v/v n-butanol: pyridine mixture 
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Procedure 
  To 0.2 ml of tissue homogenate, 0.2 ml of 8.1% SDS, 1.5 ml of 20% acetic 
acid (pH 3.5) and 1.5 ml of 0.8% TBA were added. The mixture was made up to 4 ml 
with water and then heated in a water bath at 95.8ºC for 60 min using glass ball as a 
condenser. After cooling, 1 ml of water and 5 ml of n-butanol: pyridine (15:1 v/v) 
mixture were added and shaken vigorously. After centrifugation at 4000 rpm for 10 
min, the organic layer was taken and its absorbance was measured at 532 nm. The 
level of MDA was expressed as nmoles of mg of tissue. 
6.8 ANALYSIS OF ENZYMATIC ANTIOXIDANTS PARAMETERS 
6.8.1 Estimation of superoxide dismutase (SOD) 
237
 
This enzyme catalyzes the dismutation of superoxide anion (O2-.) to hydrogen 
peroxide and molecular oxygen in the following manner 
 
 
The enzyme activity was assayed by the method of Misra and Fridovich, 1972 
Reagents 
  0.1 M Carbonate-bicarbonate buffer; pH 10.2. 
 0.6 mM EDTA solution 
 1.8 mM Epinephrine (prepared in situ) 
  Absolute ethanol. 
  Chloroform 
Procedure 
        0.1 ml of tissue homogenate was added to the tubes containing 0.75 ml ethanol 
and 0.15 ml chloroform (chilled in ice) and centrifuged. To 0.5 ml of supernatant, 
added 0.5 ml of 0.6 mM EDTA solution and 1 ml of 0.1 M carbonate-bicarbonate (pH 
10.2) buffer. The reaction was initiated by the addition of 0.5 ml of 1.8 mM 
epinephrine (freshly prepared) and the increase in absorbance at 480 nm was 
measured. The unit for superoxide dismutase (SOD) is nmoles/mg of protein. 
                 H2O + 2O2
-.
 + 2H
+
  2H2O2 + O2 
  MATERIALS AND METHODS

DEPARTMENT NOF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 

6.8.2 Estimation of Catalase (CAT).
238 
This enzyme catalyzes conversion of hydrogen peroxide into water and 
molecular oxygen. 
 
  
The enzyme activity was assayed by the method of Sinha ,1972. 
Reagents 
 Dichromate-acetic acid reagent: 5% potassium dichromate in water was 
mixed with glacial acetic acid in the ratio of 1:3 (v/v). 
 0.01 M Phosphate buffer; pH 7.0. 
 0.2M Hydrogen peroxide 
Procedure 
0.1 ml of the tissue homogenate was added to the reaction mixture containing 
1ml of 0.01 M phosphate buffer (pH 7.0) pre-warmed to 37°C, 0.4 ml of distilled 
water and the mixture was incubated at 37°C. The reaction was initiated by the 
addition of 0.5 ml of 0.2 M hydrogen peroxide and the reaction mixture was 
incubated at 37°C for one minute. The reaction was terminated by the addition of  
2 ml of dichromate-acetic acid reagent after15, 30, 45, and 60 seconds. Standard 
hydrogen peroxide in the range of 4-20 l/ moles were taken and treated in the same 
manner. All the tubes were heated in a boiling water bath for 10 minutes, cooled and 
the green colour that developed was read at 590 nm against blank containing all 
components except the enzyme. Catalase activity was expressed in U/mg protein. 
6.8.3 Estimation of glutathione peroxidase (GPx) 
239 
Glutathione peroxidase activity was determined according to the method of 
Hafemann et al. (1974). The activity of GPx was determined by measuring the 
decrease in GSH Content after incubating the sample in the presence of H2O2 and 
NaN3. 
 
 
H2O2 + 2 GSH 2H2O + 2 GSSG 
                     2H2O2  2H2O + O2 
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Reagents 
 5 mM GSH 
 25 mM H2O2 
 25 mM NaN3 
 Phosphate Buffer (0.05 mM, pH 7) 
 1.65 % HPO32 
 0.4 M Na2HPO4 
 1 mM DTNB 
Procedure 
Tissue homogenate (approximately 0.5 mg protein) was incubated with 0.1 ml 
of 5mM GSH, 0.1 ml of 1. 25 mM H2O2, 0.1ml of 25 mM NaN3 and phosphate buffer 
(0.05 mM, pH 7) in a total volume of 2.5 ml at 37oC for 10 min. The reaction was 
stopped by adding 2 ml of 1.65 % HPO32- and the reaction mixture was centrifuged 
at 1500 rpm for 10 min. 2 ml of the supernatant was mixed with 2 ml 0.4 M 
Na2HPO4 and 1ml of 1mM DTNB. The absorbance of the yellow colored complex 
was measured at 412 nm after incubation for 10 min at 37oC against distilled water. 
A sample without the tissue homogenate processed in the same way was kept as 
non enzymatic reaction. 
 
6.9 ANALYSIS OF NON ENZYMATIC ANTIOXIDANT PARAMETERS 
6.9.1 Estimation of Reduced Glutathione (GSH) 
240 
The most widely used method for the determination of GSH in biological 
samples is by Ellman reagent (DTNB), which reacts with sulfydryl compounds to give 
a relatively stable yellow color. This compound is water soluble and the color formed 
is proportional to the amount of GSH. To 0.5 ml of citrated blood, 0.5 ml of 5% 
trichloro acetic acid (TCA) solution was added to precipitate the proteins and 
centrifuged at 3000 rpm for 20 min. To 0.1 ml of supernatant, 1 ml of sodium 
phosphate buffer and 0.5 ml of DTNB reagent was added. The absorbance of the 
yellow color developed was measured at 412 nm (Ellman,1959). 
Reagents 
 TCA (5%) 
  Phosphate buffer (0.2M, pH 8.0) 
  DTNB (0.6mM in 0.2M phosphate buffer) 
  Standard GSH (10nmoles/ml of 5% TCA) 
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Procedure 
The supernatant (0.1ml) was made up to 1.0ml with 0.2M sodium phosphate 
buffer (pH 8.0). Standard GSH corresponding to concentrations ranging between 2 
and 10 n moles were also prepared. Two ml of freshly prepared DTNB solution was 
added and the intensity of the yellow colour developed was measured in a 
spectrophotometer (Genesys 10-S, USA) at 412nm after 10 minutes. The values are 
expressed as n moles GSH/g sample. 
 
6.8 HISTOPATHOLOGICAL STUDY 
232
  
           Hematoxylin, a basic dye is oxidized to hematein with a mordant, a metallic 
ion such as the salts of aluminium. The positively charged aluminium-hematein 
complex combines with the negatively charged phosphate groups of the nucleic 
acids (DNA and RNA) forming blue/purple colour, which is characteristic of 
hematoxylin stains. Eosin is an acidic dye, which is considered to have a selective 
affinity for the basic parts of the cell, i.e., the cytoplasm. Thus, the hematoxylin and 
eosin (H & E) stain is used to demonstrate different structures of the tissue. 
             The various steps involved in the preparation of tissues for histological 
studies are as follows: 
1. Fixation 
 In order to avoid tissue by the lysosomal enzymes and to preserve its physical 
and chemical structure, a bit of tissue from each organ was cut and fixed in bouin’s 
fluid immediately after removal from the animal body. The tissues were fixed in 
bouin’s fluid for about 24 hours. The tissues were then taken and washed in glass 
distilled water for a day to remove excess of picric acid. 
2. Dehydration 
 The tissues were kept in the following solutions for an hour each; 30%, 50%, 
70% and 100% alcohol. Inadequately dehydrated tissues cannot be satisfactorily 
infiltered with paraffin. At the same time over dehydration results in making the 
tissues brittle, which would be difficult for sectioning. So, careful precautions shoule 
be followed while performing the dehydration process. 
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3. Clearing 
 Dealcoholization or replacement of alcohol from the tissues with a clearing 
agent is called as clearing. Xylene was used as the clearing agent for one or two 
hours, two or three times. Since, the clearing agent is miscible with both dehydration 
and embedding agents, it permits paraffin to infilterate the tissues. So, the clearing 
was carried out as the next step after dehydration to permit tissue spaces to be filled 
with paraffin. The tissues were kept in the clearing agent till they become transparent 
and impregnated with xylene. 
4. Impregnation 
 In this process the clearing agent xylene was placed by paraffin wax. The 
tissues were taken out of xylene and were kept in molten paraffin embedding bath, 
which consists of metal pots filled with molten wax maintained at about 50oC. The 
tissues were given three changes in the molten wax at half an hour intervals. 
5. Embedding 
 The paraffin wax used for embedding should be fresh and heated upto the 
optimum melting point at about 56–58oC. A clear glass plate was smeared with 
glycerine. L-shaped mould was placed on it to from a rectangular cavity. The molten 
paraffin wax was poured and air bubbles were removed by using a hot needle. The 
tissue was placed in the paraffin and oriented with the surface to be sectioned. Then 
the tissue was pressed gently towards the glass plate to make settle uniformly with a 
metal pressing rod and allowed the wax to settle and solidity room temperature. The 
paraffin block was kept in cold water for cooling. 
6. Section Cutting 
 Section cutting was done with a rotatory microtome. The excess of paraffin 
around the tissue was removed by trimming, leaving ½ cm around the tissue. Then 
the block was attached to the gently heated holder. Additional support was given by 
some extra wax, which was applied along the sides of the block. Before sectioning, 
all set screws holding the object holder and knife were hand tightened to avoid 
vibration. To produce uniform sections, the microtome knife was adjusted to the 
proper angle in the knife holder with only the cutting edge coming in contact with the 
paraffin block. The tissue was cut in the thickness range of about 7µm. 
  MATERIALS AND METHODS

DEPARTMENT NOF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 

7. Flattening and Mounting of Sections 
 The procedure was carried out in tissue flotation warm water bath. The 
sections were spread on a warm water bath after they were detached from the knife 
with the help of hair brush. Dust free clean slides were coated with egg albumin over 
the whole surface. Required sections were spread on clean slide and kept at room 
temperature. 
8. Staining of Tissue Sections 
 The sections were stained as follows; deparaffinization with xylene two times 
each for five minutes 
 Dehydration through descending grades of ethyl alcohol 
 100% alcohol (absolute) - 2 minute 
 90% alcohol - 1minute 
 50% alcohol - 1 minute 
 Staining with Ehrlich’s Haemaoxylin was done for 15-20 minutes. Then the 
sectioned tissues were thoroughly washed in tap water for 10 minutes. Rinsed with 
distilled water and stained with Eosin. Dehydration again done with ascending 
grades of alcohol, 
 70% alcohol - 2 minute 
 90% alcohol - 2 minute 
 100%alcohol - 1 minute 
Finally the tissues were cleared with xylene two times, each for about 3 minutes 
interval. 
9. Mounting 
 On the stained slide, DPX mountant was applied uniformly and microglass 
cover slides were spread. The slides were observed in Nikon microscope and 
microphotographs were taken. 
6.9 STATISTICAL ANALYSIS 
 Results were expressed as Mean ± SEM. The data were analyzed by using 
one way analysis of variance (ANOVA) followed by Tukey's Multiple Comparison 
Test. P value < 0.05 was considered as statistically significant. Data were processed 
with graph pad prism 5.0 software. 
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7. RESULTS 
The Tamrindus indica Linn (Family: Fabaceae) was selected, on the basis of 
ethanobotanical information which reveals its uses against one of the most 
hazardous diseases. 
 Tamrindus indica Linn is grown almost in the Tamilnadu and Kerala. This 
medicinal plant possesses many pharmacological activities based upon the 
phytochemical constituents of it. 
The fruit pulp of Tamrindus indica Linn was used to treat Nephrotoxic 
condition. Detailed pharmacognostical and preliminary phytochemical investigations 
were taken to prove its appropriate identification and rationalized its use as a drug of 
therapeutic importance. 
 Extracting values of crude drug were useful for their evaluation. Further, these 
values indicated the nature of the constituents present in the crude drug. The small 
pieces of the fruit pulps of Tamrindus indica Linn was subjected for continuous hot 
percolation using 95% ethanol as a solvent using a Soxhlet apparatus. The 
percentage of extract was calculated. The result was tabulated in the table-5. 
Table-5 
Results of the Percentage yield of EETI 
Drug Tamarindus indica Linn. 
Solvent Ethanol 
Colour Dark Brownish 
Consistency Semi solid 
Percentage yield 22 % w/w 
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7.1 Preliminary phytochemical studies 
Table no-5:  Results of the Preliminary Phytochemical Constituents present in 
ethanolic extract of Tamarindus indica Linn.  
Table-6 
Results of preliminary phytochemical analysis of EETI 
Phyto-constituents Tamarindus indica Linn 
Carbohydrate Present 
Reducing sugar Present 
Tannins Present 
Flavonoids Present 
Anthroquinone Present 
Saponins Present 
Alkaloids Present 
Glycosides Present 
Terpenes Present 
Phytosterols Absent 
 
RESULT 
Ethanolic extract of the whole plants of Tamarindus indica Linn (EETI) was 
subjected to various phytochemical tests, which showed the presence of 
carbohydrates, reducing sugars, glycosides, tannins, flavonoids, Anthroquinone, 
Saponins, Alkaloids, Glycosides and Terpenes. 
 
  RESULTS

DEPARTMENT OF PHARMACOLOGY, THE ERODE COLLEGE OF PHARMACY, ERODE 	

7.2 Assessment of general biochemical parameters 
7.2.1 Assessment of urine volume 
 The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on urine volume. 
Table-7 
Results of the effect of EETI on urine volume in cisplatin induced Nephrotoxic 
rats 
 
Groups 
 
Drug Treatment Urine Volume 
I 
Normal Control 
(0.5% DMSO) 
10.85± 
0.223 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
5.90± 
0.762 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
10.81± 
0.24*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
9.17± 
0.40* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
9.70± 
0.28*** 
 
 
   Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on urine volume in cisplatin induced 
Nephrotoxic rats 
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Fig. No: 8 
RESULTS 
The urine volume were measured were showed in Table no-7 and Fig. no-8. 
The Nephrotoxic control (Group 2) showed significant decrease in urine 
volume when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in urine volume 
when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
urine volume when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
urine volume when compared to the Nephrotoxic control (Group 2). 
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7.2.2 Assessment of Body weight 
 The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on body weight. 
Table-8 
Results of the effect of EETI on  Body weight in cisplatin induced Nephrotoxic 
rats 
 
Groups 
 
Drug Treatment Body weight 
I 
Normal Control 
(0.5% DMSO) 
250± 
3.406 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
159.33± 
2.658 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
234.83± 
4.355*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
205.83± 
3.43* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
222± 
3.742*** 
 
Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on serum creatinine level on cisplatin 
induced Nephrotoxicity in rats 
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Fig. No: 9 
 
RESULTS 
The body weight were measured were showed in Table no-8 and Fig. no-9. 
The Nephrotoxic control (Group 2) showed significant decrease in body 
weight when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in body weight 
when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
body weight when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
body weight when compared to the Nephrotoxic control (Group 2). 
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7.3 Assessment of serum biochemical parameters 
7.3.1 Serum creatinine level 
 The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on serum creatinine level. 
TABLE-9 
Results of the effect of the EETI on serum Creatinine on Cisplatin induced 
Nephrotoxicity in rats 
 
Groups 
 
Drug Treatment Serum creatinine 
I 
Normal Control 
(0.5% DMSO) 
0.67± 
0.055 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
4.77± 
0.131 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
0.75± 
0.020*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
1.47± 
0.206* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
0.82± 
0.062*** 
 
Values were given in Mean ±SEM;  
  *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on serum creatinine level on cisplatin 
induced Nephrotoxicity in rats 
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Fig. no-10 
 
RESULTS 
The serum creatinine were measured were showed in Table no-9 and Fig. no-
10. 
The Nephrotoxic control (Group 2) showed significant increase in serum 
creatinine level when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant decrease in serum 
creatinine level when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant decrease in 
serum creatinine level when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant decrease in 
serum creatinine level when compared to the Nephrotoxic control (Group 2). 
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7.3.2 Serum Blood urea nitrogen (BUN) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on serum Blood urea nitrogen (BUN) level. 
Table-10 
Results of the effect of the EETI on serum Blood urea nitrogen on Cisplatin 
induced Nephrotoxicity in rats 
 
Groups 
 
Drug Treatment 
Serum blood urea 
nitrogen (BUN) 
I 
Normal Control 
(0.5% DMSO) 
23.66± 
0.505 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
58.77± 
0.792 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
24.15± 
0.50*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
30.02± 
0.94* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
24.55± 
0.55*** 
 
 
Values were given in Mean ±SEM;  
  *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on serum Blood urea nitrogen 
parameters on cisplatin induced Nephrotoxicity in rats 
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Fig. No: 11 
RESULTS 
The serum Blood urea nitrogen (BUN) level were measured were showed in  
Table no-10 and Fig. no-11. 
The Nephrotoxic control (Group 2) showed significant increase in serum 
Blood urea nitrogen (BUN) level when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant decrease in serum Blood 
urea nitrogen (BUN) level when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant decrease in 
serum Blood urea nitrogen (BUN) level when compared to the Nephrotoxic control 
(Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant decrease in 
serum Blood urea nitrogen (BUN) level when compared to the Nephrotoxic control 
(Group 2). 
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7.4 Assessment of urine biochemical parameters 
7.4.1 Assessment of creatinine clearence 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on creatinine clearance. 
 
Table-11 
Results of the effect of EETI on creatinine clearence in cisplatin induced  
Nephrotoxic rats 
 
Groups 
 
Drug Treatment 
Creatinine 
clearance 
I 
Normal Control 
(0.5% DMSO) 
19.80± 
1.302 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
5.05± 
0.445 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
18.265± 
0.512*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
14.74± 
0.746* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
17.20± 
1.146*** 
 
 
   Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on creatinine clearance in cisplatin 
induced Nephrotoxic rats 
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Fig. no- 12 
 
RESULTS 
The creatinine clearence were measured were showed in  
Table no-11 and Fig. no-12. 
The Nephrotoxic control (Group 2) showed significant decrease in creatinine 
clearence when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in creatinine 
clearence when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
creatinine clearence when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
creatinine clearence when compared to the Nephrotoxic control (Group 2). 
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7.5 Assessment of oxidative stress parameter 
7.5.1 Assessment of Malondialdehyde (MDA) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on malondialdehyde (MDA). 
Table-12 
Results of the effect of EETI on Malondialdehyde (MDA) in cisplatin induced 
Nephrotoxic rats 
 
Groups 
 
Drug Treatment 
Malondialdehyde 
(MDA) 
I 
Normal Control 
(0.5% DMSO) 
7.61± 
0.470 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
15.44± 
0.409 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid (mg/kg) 
7.86± 
0.118*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
8.77± 
0.427** 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
7.66± 
0.238*** 
 
Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on Malondialdehyde (MDA) in cisplatin 
induced Nephrotoxic rats 
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Fig. no- 13 
 
RESULTS 
The malondialdehyde (MDA) were measured were showed in  
Table no-12 and Fig. no-13. 
The Nephrotoxic control (Group 2) showed significant increase in 
malondialdehyde (MDA) when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant decrease in 
malondialdehyde (MDA) when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant decrease in 
malondialdehyde (MDA) when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant decrease in 
malondialdehyde (MDA) when compared to the Nephrotoxic control (Group 2). 
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7.6 Assessment of enzymatic antioxidant parameters 
7.6.1 Assessment of superoxide dismutase (SOD) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on superoxide dismutase (SOD). 
Table-13 
Results of the effect of EETI on superoxide dismutase (SOD) in cisplatin 
induced Nephrotoxic rats 
 
Groups 
 
Drug Treatment 
Superoxide 
dismutase (SOD) 
I 
Normal Control 
(0.5% DMSO) 
19.56± 
0.591 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
7.53± 
0.423 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
18.50± 
0.44*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
11.89± 
0.303* 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
15.57± 
0.375*** 
 
 
   Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on superoxide dismutase (SOD) in 
cisplatin induced Nephrotoxic rats 
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Fig. no- 14 
 
RESULTS 
The superoxide dismutase (SOD) were measured were showed in  
Table no-13 and Fig. no-14. 
The Nephrotoxic control (Group 2) showed significant decrease in superoxide 
dismutase (SOD) when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in superoxide 
dismutase (SOD) when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
superoxide dismutase (SOD) when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
superoxide dismutase (SOD) when compared to the Nephrotoxic control (Group 2). 
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7.6.2 Assessment of Catalase (CAT) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on Catalase (CAT). 
Table-14 
Results of the effect of EETI on Catalase (CAT) in cisplatin induced 
Nephrotoxic rats 
 
Groups 
 
Drug Treatment Catalase (CAT) 
I 
Normal Control 
(0.5% DMSO) 
220.31± 
0.52 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
104.94± 
0.37 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
200.03± 
0.612*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
158.39± 
4.091** 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
181± 
0.265*** 
 
Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on Catalase (CAT) in cisplatin induced 
Nephrotoxic rats 
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 Fig. no- 15 
 
RESULTS 
The Catalase (CAT) were measured were showed in  
Table no-14 and Fig. no-15. 
The Nephrotoxic control (Group 2) showed significant decrease in Catalase 
(CAT) when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in Catalase (CAT) 
when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
Catalase (CAT) when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
Catalase (CAT) when compared to the Nephrotoxic control (Group 2). 
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7.6.3 Assessment of Glutathione peroxidise (GPx) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on Glutathione peroxidise (GPx). 
Table-15 
Results of the effect of EETI on Glutathione peroxidise (GPx) in cisplatin 
induced Nephrotoxic rats 
 
Groups 
 
Drug Treatment 
Glutathione 
peroxidise (GPx) 
I 
Normal Control 
(0.5% DMSO) 
23.29± 
0.45 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
14.48± 
0.448 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
21.39± 
0.37*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
16.33± 
0.399** 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
19.26± 
0.228*** 
Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on Glutathione peroxidise (GPx) in 
cisplatin induced Nephrotoxic rats 
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Fig. no- 16 
 
RESULTS 
The Glutathione peroxidise (GPx) were measured were showed in  
Table no-15 and Fig. no-16. 
The Nephrotoxic control (Group 2) showed significant decrease in Glutathione 
peroxidise (GPx) when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in Glutathione 
peroxidise (GPx) when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
Glutathione peroxidise (GPx) when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
Glutathione peroxidise (GPx) when compared to the Nephrotoxic control (Group 2). 
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7.7 Assessment of non-enzymatic antioxidant parameter 
7.7.1 Assessment of Reduced glutathione (GSH) 
The effects of the different doses of ethanolic extract of Tamarindus indica 
Linn on Reduced glutathione (GSH). 
Table-16 
Results of the effect of EETI on Reduced glutathione (GSH) in cisplatin 
induced Nephrotoxic rats 
 
Groups 
 
Drug Treatment 
Reduced 
glutathione (GSH) 
I 
Normal Control 
(0.5% DMSO) 
20.15± 
0.776 
II 
Nephrotoxic Control 
Cisplatin (0.75%) 
8.28± 
0.201 
III 
Reference Control 
Cisplatin (0.75%) + 
Lipoic acid 
(50mg/kg) 
18.47± 
0.488*** 
IV 
Cisplatin (0.75%) + 
EETI (200mg/kg) 
14.37± 
0.280** 
V 
Cisplatin (0.75%) +  
EETI (400mg/kg) 
16.33± 
0.566*** 
 
Values were given in Mean ±SEM;  
   *P<0.05, ** P<0.01 and** *P<0.001 Vs Nephrotoxic Control 
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Diagrammatic representation of EETI on Reduced glutathione (GSH) in 
cisplatin induced Nephrotoxic rats 
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Fig. no- 17 
 
RESULTS 
The Reduced glutathione (GSH) were measured were showed in  
Table no-16 and Fig. no-17. 
The Nephrotoxic control (Group 2) showed significant decrease in Reduced 
glutathione (GSH) when compared to the normal control (Group1).  
Standard (Group 3) showed statistically significant increase in Reduced 
glutathione (GSH) when compared to Nephrotoxic control (Group 2). 
 EETI 200 mg/kg treated (Group 4) showed statistically significant increase in 
Reduced glutathione (GSH) when compared to the Nephrotoxic control (Group 2).  
EETI 400mg/kg treated (Group 5) showed statistically significant increase in 
Reduced glutathione (GSH) when compared to the Nephrotoxic control (Group 2). 
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7.8 HISTOPATHOLOGICAL STUDIES 
a) Normal group 
  Section of the kidney of normal control rat showed, 
• Arrangement of nephrotic bundles appears normal, both cortex and medulla 
appears normal. 
• Normal glomerular structure with regularly arranged podocytes was observed. 
• No signs of degeneration and edema and no signs of inflammation like 
glomerulonephritis. 
• Proximal and Distal convoluted tubule appears normal and intact. 
• No signs of karyolysis. 
b) Nephrotoxic group 
 Section of the kidney of Nephroprotective control rat showed the following, 
• Appearance of coagulative and diffused necrosis 
• Severe Glomerulonephritis- Glomerular condensation and appearance of 
inflammatory cells 
• Marked signs of hemorrhage, edema and narrowed renal arterioles. 
c) Standard group 
Section of the kidney of lipoic acid treated group rat showed normal histology 
of kidney and a20bsence of necrosis. 
d) Extract treated groups 
Section of the kidney treated with low dose (200mg/kg) of EETI showed 
• Moderate tubular degeneration with mild edema and 
• Necrotic changes with swollen tubular epithelium. 
Section of the kidney treated with high dose (400mg/kg) of EETI showed 
• Moderated signs of regeneration with occurrence of chromatolysis was 
observed in the tubular structure and 
• Stripping of tubular epithelium with inter tubular edema.  
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Group IV       
Group 
V
 
Fig. no- 18: Photomicrographs of kidney tissue section Group I- Normal 
control, Group II- Nephrotoxic Control, Group III- Reference Control,  
Group IV- EETI (200mg/kg),   Group V- EETI (400mg/kg) 
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8. DISCUSSION 
 Nephrotoxicity is a common clinical syndrome defined as a rapid decline in 
renal function resulting in abnormal retention of serum creatinine and blood urea, 
which must be excreted. 
There are few chemical agents to treat acute renal failure. Studies reveal back 
synthetic nephroprotective agents have adverse effect besides reduce 
nephrotoxicity. 
There is a growing interest of public in traditional medicine, particularly in the 
treatment of nephrotoxicity partly because of limited choice in the pharmacotherapy. 
Many plants have been used for the treatment of kidney failure in traditional system 
of medicine throughout the world. Indeed along with the dietary measures, plant 
preparation formed the basis of treatment of disease until the introduction of 
allopathic medicine. 
Ethnomedicinal plants can be used to help forestall the need of dialysis by 
treating the causes and effect of renal failure, as well as reducing the many adverse 
effect of dialysis. 
  The phytochemicals found to be present in the fruit pulp extract are the 
flavanoids, terpenoids, alkaloids, tannins, saponins and anthraquinones. Among 
them tannins, triterpenoids, flavanoids and saponins could be responsible for 
antioxidant property as these phytoconstituents are already reported to have 
antioxidant activity.216 
Acute toxicity studies revealed the non-toxic nature of the ethanolic extract of 
Tamarindus indica Linn. There was no lethality or any toxic reactions found with high 
dose (2000 mg/kg body weight) till the end of the study. According to the OECD 423 
guidelines (Acute Oral Toxicity: Acute Toxic Classic Method), an LD50 dose of  
2000 mg/kg and above was considered as unclassified so the ethanolic extract of 
Tamarindus indica Linn was found to be safe. 
Cisplatin causes damage to nuclear and mitochondrial DNA and production of 
reactive oxygen species (ROS) which lead to activation of both mitochondrial and 
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non mitochondrial pathways of apoptosis and necrosis. Mitochondrial energetic are 
also disrupted by cisplatin and may contribute to nephrotoxicity.47  
In present study, the rats treated with single dose of Cisplatin shown marked 
reduction of body weight as compared to normal group also caused a marked 
reduction of glomourular filtration rate, which is accompanied by increase in serum 
creatinine level and declain in creatinine clearence indicating induction of acute renal 
failure.241 with Tamarindus indica Linn at the dose level of 200 and 400 mg/kg body 
weight for 15 days significantly lowered the serum level of creatinine with a 
significant weight gain, increased urine output and creatinine clearence when 
compared with the nephrotoxic control group.  
Cisplatin administration to control rats produced a typical pattern of 
nephrotoxicity which was manifested by marked increase in serum blood urea 
nitrogen (BUN).65 Tamarindus indica Linn supplementation to Cisplatin treated rats 
recorded decrement in levels of blood urea nitrogen (BUN) in plasma. 
The elevated level of malondialdehyde (MDA), a marker of lipid preroxidation, 
indicates increased free radical generation in the Cisplatin induced nephrotoxicity. 
Cisplatin induced increment in malondialdehyde (MDA) content of plasma was 
significantly prevented by Tamarindus indica Linn treatment in the present study. 
Therefore, the significantly lower levels of malondialdehyde (MDA) in the kidney 
tissues of treated groups as compared with the Cisplatin group indicate attenuation 
of lipid peroxidation. This was probably due to less damage by oxygen free radicals 
with Tamarindus indica Linn. The involvement of oxygen free radicals in tissue injury 
is well established.66 
Decrement in activity levels of renal Superoxide dismutase (SOD),  
Catalase (CAT) and Reduced Glutathione (GSH) following Cisplatin treatment are in 
accordance with previous report on Cisplatin induced suppression of endogenous 
enzymatic antioxidant machinery.66 Tamarindus indica Linn treatment efficiently 
prevented Cisplatin induced decrease in activity levels of superoxide dismutase 
(SOD), Catalase (CAT) and Reduced Glutathione (GSH).242 A relationship between 
nephrotoxicity and oxidative stress has been confirmed in many experimental 
models. 
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Biological systems protect themselves against the damaging effects of 
activated species by several means. These include free radical scavengers and 
chain reaction terminators such as GPX system. Glutathione peroxidise (GPx) is a 
seleno-enzyme two third of which is present in the cytosol and one-third in the 
mitochondria, It catalyses the reaction of hydro-peroxides with reduced Glutathione 
to form Glutathione disulphide (GSSG) and the reduction product of the  
hydro-peroxide.243Effect of Tamarindus indica Linn on Glutathione peroxidise (GPx) 
in experimental rats study were significantly reduced in cisplatin treated rats than in 
the experimental control rats. Decrement in the activity of renal GPx following 
cisplatin treatment are due to suppression of endogenous enzymatic antioxidant 
machinery. Supplementation with Tamarindus indica Linn to Cisplatin treated rats 
resultedin near normal activity of glutathione peroxidise (GPx). 
Based on the above results, it was concluded that Tamarindus indica Linn 
exerted statistically significant Nephroprotective activity against cisplatin induced 
Nephrotoxic rats. 
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9. SUMMARY AND CONCLUSION 
 The present study was undertaken to scientifically evaluate the 
nephroprotective activity of the ethanolic extract of fruit pulps of Tamarindus indica 
Linn. 
 The phytochemical investigation revealed the presence of carbohydrate, 
alkaloids, flavanoids, glycosides, saponins, tannins, phenols and anthroquinone in 
EETI. 
 The administration of cisplatin during experimentation is effectively induced 
apoptosis and necrosis, which was similar to acute renal failure in human. Therefore 
it is an effective and an ideal model for nephrotoxicity research. 
 The evaluation of renal parameters on nephrotoxic rats with EETI showed 
significantly elevate the attenuated body weight, urine volume, creatinine clearance 
and significant reduce in elevated serum creatinine level, which supports its 
Nephroprotective activity. 
The cisplatin induced rats showed elevated levels of serum blood urea 
nitrogen (BUN) and lipid peroxidation parameter like malondialdehyde (MDA) which 
was significantly decreased with treatment of EETI, which proves it having 
Nephroprotective activity. 
 The Nephrotoxic rats also showed the reduced levels of enzymatic antioxidant 
like sulphoxide dismutase (SOD), glutathione peroxidise (GPx) and Catalase (CAT), 
and non-enzymatic antioxidant like Reduced glutathione (GSH), which was 
significantly increased with treatment of EETI, which showed its antioxidant activity 
due to the Flavonoids which is present in the extract.  
Histopathological studies on isolated kidney revealed that the EETI, reversed 
the kidney damage and also restored normal kidney architecture. 
In summary, the fruit pulp of Tamarindus indica Linn in an ethanolic extract 
showed statistically significant nephroprotective activity. 
The plant extract proved to have nephroprotective potentials may because of 
its known flavonoid contents and antioxidant properties. 
 There is a scope for further investigation on the histopathology of liver and 
spleen and clinical studies that are required to elucidate the active phytoconstituents 
with potent nephroprotective activity. 
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10. FUTURE PROSPECTIVES 
1. There is a scope for further investigation on the histopathology of liver and 
spleen, and clinical studies that are required to elucidate the active 
phytoconstituents with potent Nephroprotective activity. 
2. A lead molecule having the Nephroprotective activity can be isolated from the 
ethanolic extract of the fruit pulps of Tamarindus indica Linn. 
3. A Suitable formulation of the isolated lead molecule can be designed. 
4. The formulated compound can be subjected to clinical trials in healthy human 
volunteers or diseased persons. 
5. The formulated compound can be put for patency and after that it can be 
marketed. 
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